<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29554938</article-id><article-id pub-id-type="pmc">5859525</article-id><article-id pub-id-type="publisher-id">1432</article-id><article-id pub-id-type="doi">10.1186/s12967-018-1432-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9726-1498</contrib-id><name><surname>Eftimie</surname><given-names>Raluca</given-names></name><address><phone>+44 (0) 1382 384488</phone><email>r.a.eftimie@dundee.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hassanein</surname><given-names>Esraa</given-names></name><address><email>esraa_nob22@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0397 2876</institution-id><institution-id institution-id-type="GRID">grid.8241.f</institution-id><institution>Division of Mathematics, </institution><institution>University of Dundee, </institution></institution-wrap>Dundee, DD1 4HN UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0639 9286</institution-id><institution-id institution-id-type="GRID">grid.7776.1</institution-id><institution>Biophysics Department, Faculty of Science, </institution><institution>Cairo University, </institution></institution-wrap>12613 Giza, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>16</volume><elocation-id>73</elocation-id><history><date date-type="received"><day>28</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Early cancer diagnosis is one of the most important challenges of cancer research, since in many cancers it can lead to cure for patients with early stage diseases. For epithelial ovarian cancer (which is the leading cause of death among gynaecologic malignancies) the classical detection approach is based on measurements of CA-125 biomarker. However, the poor sensitivity and specificity of this biomarker impacts the detection of early-stage cancers.</p></sec><sec><title>Methods</title><p id="Par62">Here we use a computational approach to investigate the effect of combining multiple biomarkers for ovarian cancer (e.g., CA-125 and IL-7), to improve early cancer detection.</p></sec><sec><title>Results</title><p id="Par63">We show that this combined biomarkers approach could lead indeed to earlier cancer detection. However, the immune response (which influences the level of secreted IL-7 biomarker) plays an important role in improving and/or delaying cancer detection. Moreover, the detection level of IL-7 immune biomarker could be in a range that would not allow to distinguish between a healthy state and a cancerous state. In this case, the construction of solution diagrams in the space generated by the IL-7 and CA-125 biomarkers could allow us predict the long-term evolution of cancer biomarkers, thus allowing us to make predictions on cancer detection times.</p></sec><sec><title>Conclusions</title><p id="Par64">Combining cancer and immune biomarkers could improve cancer detection times, and any predictions that could be made (at least through the use of CA-125/IL-7 biomarkers) are patient specific.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ovarian cancer</kwd><kwd>Mathematical model</kwd><kwd>CA-125 biomarker</kwd><kwd>IL-7 biomarker</kwd><kwd>Cancer detection times</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par9">Ovarian cancer is the most fatal of all gynecologic malignancies, since it is usually detected in the later stages when the 5-year survival is only between 37&#x02013;44% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Until an effective treatment is found, early diagnosis (when the tumour can be treated more effectively) is the only option to improve patient outcome. In fact, early cancer detection could increase patients 5-year survival rates to even 90% [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par10">As emphasised in various studies [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], currently there are no non-invasive methods that could accurately detect early-stage ovarian cancers. The classical approach for ovarian cancer diagnosis involves the serum tumour biomarker CA-125 (carbohydrate antigen 125), which is elevated in the serum of most women with ovarian cancer [<xref ref-type="bibr" rid="CR7">7</xref>]. However, despite its widespread clinical use, this biomarker does not seem to lead to significant increase in the survival rates of asymptomatic women [<xref ref-type="bibr" rid="CR3">3</xref>]. Unfortunately, CA-125 lacks both sensitivity and specificity required for the efficient screening of ovarian cancers (where sensitivity is defined as the proportion of patients with ovarian cancer correctly identified by CA-125, while specificity is the proportion of patients without ovarian cancer correctly identified by CA-125 [<xref ref-type="bibr" rid="CR8">8</xref>]).</p><p id="Par11">To address this issue related to the CA-125 biomarker, the last 10&#x02013;15 years have seen the development of various multimodal strategies that combine multiple diagnostic markers/tools [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. For example, we note the combination of CA-125 with transvaginal sonography [<xref ref-type="bibr" rid="CR11">11</xref>], with human epididymal secretory protein 4 (HE4) [<xref ref-type="bibr" rid="CR12">12</xref>], or with mesothelin [<xref ref-type="bibr" rid="CR13">13</xref>], to investigate the possibility of improving early cancer detection. An approach that has received particular attention in the past years focuses on the use of serum cytokine levels as diagnostic and prognostic markers in ovarian cancer [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Many of these cytokines (e.g., IFN-<inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma $$\end{document}</tex-math><mml:math id="M2"><mml:mi>&#x003b3;</mml:mi></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq1.gif"/></alternatives></inline-formula>, IL-2, IL-7, G-CSF, &#x02026;) are produced by various hematopoietic and non-hematopoietic cell lines, and are involved in inflammation and immunity [<xref ref-type="bibr" rid="CR14">14</xref>]. In addition, some cytokines (such as IL-6 and IL-8) seem to be produced also by ovarian cancer cells [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par12">A cytokine that has been investigated in the context of ovarian cancer detection is IL-7 (interleukin 7) [<xref ref-type="bibr" rid="CR14">14</xref>]. This cytokine, which is produced mainly by non-hematopoietic cells (e.g., epithelial cells in the thymus, prostatic epithelium and the intestine; see [<xref ref-type="bibr" rid="CR16">16</xref>]) and by some immune cells (e.g., dendritic cells), is important for the development of B cells and T cells [<xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, IL-7 seems to have anti-tumour effects in tumours such as melanoma, prostate cancer or glioblastoma, and potential pro-tumour effects in bladder cancer by promoting cell invasion and migration [<xref ref-type="bibr" rid="CR17">17</xref>]. Since high IL-7 serum levels have been detected in ovarian cancers [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>], it has been suggested that IL-7 can be used in combination with CA-125 to distinguish between malignant and benign ovarian tumours [<xref ref-type="bibr" rid="CR14">14</xref>]. Moreover [<xref ref-type="bibr" rid="CR18">18</xref>], suggested that the elevated serum IL-7 is the result of host anti-tumour immunity.</p><p id="Par13">The use of cytokines for cancer detection seems particularly relevant in the context of recent studies which emphasise more and more the importance of immune responses in the evolution of ovarian cancer and long-term patient survival [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Despite clinical observations that ovarian cancers can induce spontaneous anti-tumour immune responses [<xref ref-type="bibr" rid="CR23">23</xref>], and that significant numbers of tumour-infiltrating lymphocytes have been found inside cancerous ovarian tissues (some immune cells being associated with improved overall survival [<xref ref-type="bibr" rid="CR22">22</xref>]), the role of the immune system in response to ovarian cancer is still not fully understood. The poor outcome of this particular type of cancer is also the result of immune cells failing to control tumour growth, due to the recruitment inside the tumour environment of suppressive immune cells such as Tregs, or the NK cells failing to recognise tumour antigens [<xref ref-type="bibr" rid="CR23">23</xref>]. However, there are not many studies in the literature that investigate the secretion of immune biomarkers (and their use for cancer detection) in the context of complex tumour&#x02013;immune interactions.</p><p id="Par14">Since mathematical approaches have been shown to be very useful on shedding light on the biological mechanisms behind various complex immune responses and on making further biological predictions [<xref ref-type="bibr" rid="CR24">24</xref>], in this study we consider such an approach to investigate computationally the interactions between tumour cells and tumour-infiltrating lymphocytes (i.e., dendritic-cell-activated CD8<inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M4"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq2.gif"/></alternatives></inline-formula> T cells), and the use of biomarkers associated with these different cells to improve cancer detection times.</p><p id="Par15">Mathematical modelling and computational approaches have recently started being used to asses the detection level of cancer biomarkers, and they usually focus on one biomarker at a time, e.g., CA-125 [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], SEAP [<xref ref-type="bibr" rid="CR27">27</xref>], uPAR [<xref ref-type="bibr" rid="CR28">28</xref>], or nanoparticles conjugated with protease-cleavable peptides [<xref ref-type="bibr" rid="CR29">29</xref>]. While many of these models are deterministic (usually described by ordinary differential equation (ODE) models), the past 10&#x000a0;years have seen also a significant increase in the development of various stochastic network-based biomarker models for the diagnosis and investigation of different cancers [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]. Generally, these network models incorporate a large number of cancer-related proteins and networks of proteins, and use them to identify the most likely biomarkers for cancer detection. Hence, the two major approaches in the literature either (i) start with simple mathematical models of basic processes and then add more complexity, or (ii) start by considering the complexity of the system, and then try to deconvolute it to identify the most important processes. Throughout this study, we consider only the first approach.</p><p id="Par16">Here, we start with a simple ODE model introduced in [<xref ref-type="bibr" rid="CR25">25</xref>] for tumour growth and CA-125 secretion, and generalise it to investigate the use of two different biomarkers (CA-125 and IL-7) on the overall detection time. We chose to focus on these two biomarkers since [<xref ref-type="bibr" rid="CR14">14</xref>] showed that IL-7 levels were strongly associated with ovarian cancer, and moreover a combination of IL-7 and CA-125 serum levels could accurately predict 69% of ovarian cancer patients. With the help of this new model, we show the importance of the heterogeneity in the immune response (which impacts the secretion level of IL-7) on the cancer detection times. Thus we show that by combining an immune biomarker with a cancer biomarker one could help improve tumour detection times in some patients, but also might delay tumour detection in other patients (depending on the level of anti-tumour immune response).</p></sec><sec id="Sec2"><title>Methods</title><p id="Par17">We start modelling the tumour dynamics by considering (as in [<xref ref-type="bibr" rid="CR25">25</xref>]) a mono-exponential model for early tumour growth (the density of tumour cells at time <italic>t</italic> being described by <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M6"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq3.gif"/></alternatives></inline-formula>). To model an early anti-tumour immune response, we then couple the equation for the evolution of tumour cells <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq4.gif"/></alternatives></inline-formula> with an equation for the evolution of immune cells <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}(t)$$\end{document}</tex-math><mml:math id="M10"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq5.gif"/></alternatives></inline-formula>: <disp-formula id="Equ1"><label>1a</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \frac{d N_{\text {T}}(t)}{dt}&#x00026;=k_{gr}N_{\text {T}}(t)-d_{t}N_{\text {T}}(t)\frac{N_{\text {I}}(t)}{h_{i}+N_{\text {I}}(t)},\end{aligned}$$\end{document}</tex-math><mml:math id="M12" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="12967_2018_1432_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>
<disp-formula id="Equ2"><label>1b</label><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \frac{d N_{\text {I}}(t)}{dt}&#x00026;=a_{i}N_{\text {T}}(t)\Big (1-\frac{N_{\text {I}}(t)}{M}\Big )-d_{i}N_{\text {I}}(t). \end{aligned}$$\end{document}</tex-math><mml:math id="M14" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em" stretchy="true">(</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>M</mml:mi></mml:mfrac><mml:mrow><mml:mo maxsize="1.623em" minsize="1.623em" stretchy="true">)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="12967_2018_1432_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p><p>Here, <inline-formula id="IEq6"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M16"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq6.gif"/></alternatives></inline-formula> is the growth rate of the ovarian cancer cells, <inline-formula id="IEq7"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M18"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq7.gif"/></alternatives></inline-formula> is the rate at which immune cells eliminate the detected tumour cells, <inline-formula id="IEq8"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M20"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq8.gif"/></alternatives></inline-formula> is the activation/proliferation of immune cells in response to tumour antigens, <inline-formula id="IEq9"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M22"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq9.gif"/></alternatives></inline-formula> is the natural half-life of immune cells, and <italic>M</italic> is the carrying capacity for the immune cells (since the body cannot support an extremely large number of activated immune cells, which would trigger a cytokine storm [<xref ref-type="bibr" rid="CR34">34</xref>]). Note that we use the saturated term <inline-formula id="IEq10"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}(t)/(h_{i}+N_{\text {I}}(t))$$\end{document}</tex-math><mml:math id="M24"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq10.gif"/></alternatives></inline-formula> to describe the immuno-modulating effect of ovarian cancer cells on the immune response, which leads to reduced anti-tumour immune responses (and subsequent cancer growth) [<xref ref-type="bibr" rid="CR35">35</xref>]. Parameter <inline-formula id="IEq11"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$h_{i}$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq11.gif"/></alternatives></inline-formula> is the half-saturation constant of immune cells that generate an anti-tumour immune response. Note that, for simplicity, here we assume that the generic immune cell population <inline-formula id="IEq12"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq12.gif"/></alternatives></inline-formula> includes both antigen-presenting cells (e.g., dendritic cells) and anti-tumour effector cells (e.g., CD8<inline-formula id="IEq13"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M30"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq13.gif"/></alternatives></inline-formula> T cells) activated by these antigen-presenting cells upon detection of tumour antigens.</p><p id="Par18">Next, we model the shedding of biomarkers by tumour and immune cells. For the CA-125 biomarker, we follow the approach in [<xref ref-type="bibr" rid="CR25">25</xref>] and assume that the equation for the change in the amount of tumour plasma biomarkers, <inline-formula id="IEq14"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{T}(t)$$\end{document}</tex-math><mml:math id="M32"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq14.gif"/></alternatives></inline-formula>, which are shed by both tumour (<inline-formula id="IEq15"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {T}}$$\end{document}</tex-math><mml:math id="M34"><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq15.gif"/></alternatives></inline-formula>) and healthy (<inline-formula id="IEq16"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{h}$$\end{document}</tex-math><mml:math id="M36"><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq16.gif"/></alternatives></inline-formula>) cells, is given as<disp-formula id="Equ3"><label>2</label><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \frac{dB_{\text {T}}(t)}{dt}=f_{ht}R_{ht}N_{h}+f_{t}R_{t}N_{\text {T}}(t)-k_{et}B_{\text {T}}(t). \end{aligned}$$\end{document}</tex-math><mml:math id="M38" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">et</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="12967_2018_1432_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula>For simplicity, we assume that the number of healthy cells does not vary significantly in time, and thus we take <inline-formula id="IEq17"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{h}=$$\end{document}</tex-math><mml:math id="M40"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq17.gif"/></alternatives></inline-formula>&#x000a0;constant (i.e., the initial number of healthy cells). Parameters <inline-formula id="IEq18"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{t}$$\end{document}</tex-math><mml:math id="M42"><mml:msub><mml:mi>f</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq18.gif"/></alternatives></inline-formula> and <inline-formula id="IEq19"><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ht}$$\end{document}</tex-math><mml:math id="M44"><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq19.gif"/></alternatives></inline-formula> are the fractions of tumour biomarker entering the tumour and the healthy vasculatures, respectively. Parameters <inline-formula id="IEq20"><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R_{t}$$\end{document}</tex-math><mml:math id="M46"><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq20.gif"/></alternatives></inline-formula> and <inline-formula id="IEq21"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R_{ht}$$\end{document}</tex-math><mml:math id="M48"><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq21.gif"/></alternatives></inline-formula> are the shedding rates of tumour biomarker from tumour and healthy cells, respectively. Finally, <inline-formula id="IEq22"><alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{et}$$\end{document}</tex-math><mml:math id="M50"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">et</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq22.gif"/></alternatives></inline-formula> is the elimination rate of tumour biomarker from plasma.</p><p id="Par19">In regard to the immune biomarkers, [<xref ref-type="bibr" rid="CR18">18</xref>] showed that the ovarian carcinoma cells rarely express IL-7, with the authors hypothesising that the elevated level of IL-7 in the serum and ascites of ovarian cancer patients was mainly from the host immune cells. Because the IL-7 biomarker can be produced by the immune cells (e.g., dendritic cells which activate the CD8<inline-formula id="IEq23"><alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M52"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq23.gif"/></alternatives></inline-formula> T cells) and by the healthy non-hematopoietic cells (<inline-formula id="IEq24"><alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{h}$$\end{document}</tex-math><mml:math id="M54"><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq24.gif"/></alternatives></inline-formula>), the equation for the change in the amount of the immune biomarker <inline-formula id="IEq25"><alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}$$\end{document}</tex-math><mml:math id="M56"><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq25.gif"/></alternatives></inline-formula> is given by<disp-formula id="Equ4"><label>3</label><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} \frac{dB_{\text {I}}(t)}{dt}=f_{hi}R_{hi}N_{h}+f_{i}R_{i}N_{\text {I}}(t)-k_{ei}B_{\text {I}}(t). \end{aligned}$$\end{document}</tex-math><mml:math id="M58" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="12967_2018_1432_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula>Here <inline-formula id="IEq26"><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}$$\end{document}</tex-math><mml:math id="M60"><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq26.gif"/></alternatives></inline-formula> and <inline-formula id="IEq27"><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{hi}$$\end{document}</tex-math><mml:math id="M62"><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq27.gif"/></alternatives></inline-formula> are the fractions of immune biomarkers (shed by immune and healthy cells) that enter the vasculatures, while <inline-formula id="IEq28"><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R_{i}$$\end{document}</tex-math><mml:math id="M64"><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq28.gif"/></alternatives></inline-formula> and <inline-formula id="IEq29"><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R_{hi}$$\end{document}</tex-math><mml:math id="M66"><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq29.gif"/></alternatives></inline-formula> are the shedding rates of the immune biomarker from immune and healthy cells. Finally, <inline-formula id="IEq30"><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}$$\end{document}</tex-math><mml:math id="M68"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq30.gif"/></alternatives></inline-formula> is the elimination rate of immune biomarker from the plasma. As before, we assume that the population of healthy cells is constant: <inline-formula id="IEq31"><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{h}=$$\end{document}</tex-math><mml:math id="M70"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq31.gif"/></alternatives></inline-formula>&#x000a0;constant.</p><p id="Par20">These tumour&#x02013;immune interactions and biomarker secretion dynamics are summarised in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>A schematic representation of the interactions between tumour cells and immune effector cells, as described by model (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>)</p></caption><graphic xlink:href="12967_2018_1432_Fig1_HTML" id="MO5"/></fig>
</p><sec id="Sec3"><title>Model parametrisation</title><p id="Par22">Table <xref rid="Tab1" ref-type="table">1</xref> contains the baseline values and ranges for the parameters associated with the tumour biomarker (CA-125), as estimated by [<xref ref-type="bibr" rid="CR25">25</xref>]. Table <xref rid="Tab2" ref-type="table">2</xref> contains the baseline values and ranges for the parameters associated with the immune response, which are estimated in the present study as follows:<list list-type="order"><list-item><p id="Par23"><italic>Immune cells turnover</italic> [<xref ref-type="bibr" rid="CR36">36</xref>] calculated the doubling time for CD8<inline-formula id="IEq53"><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M72"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq53.gif"/></alternatives></inline-formula> T cells to about 8 h, and their half-life during the contraction phase to about 41 h. This translates into the following parameter values: <inline-formula id="IEq54"><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}=\ln (2.0)/8$$\end{document}</tex-math><mml:math id="M74"><mml:mrow><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>ln</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2.0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq54.gif"/></alternatives></inline-formula>&#x000a0;h = 2.0794/day, and <inline-formula id="IEq55"><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}=\ln (2.0)/41$$\end{document}</tex-math><mml:math id="M76"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>ln</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2.0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mn>41</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq55.gif"/></alternatives></inline-formula>&#x000a0;h&#x000a0;=&#x000a0;0.4/day.</p><p>However, since our variable <inline-formula id="IEq56"><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}$$\end{document}</tex-math><mml:math id="M78"><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq56.gif"/></alternatives></inline-formula> accounts for a combination of effector CD8<inline-formula id="IEq57"><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M80"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq57.gif"/></alternatives></inline-formula> T cells and antigen-presenting dendritic cells (which detect the tumour antigens, and further induce the activation and proliferation of CD8<inline-formula id="IEq58"><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M82"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq58.gif"/></alternatives></inline-formula> T cells), we need to discuss also the turnover of dendritic cells&#x02014;which can influence the overall dynamics of <inline-formula id="IEq59"><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}$$\end{document}</tex-math><mml:math id="M84"><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq59.gif"/></alternatives></inline-formula> population in Eq. (<xref rid="Equ2" ref-type="">1b</xref>), as suggested by [<xref ref-type="bibr" rid="CR37">37</xref>]. In fact, [<xref ref-type="bibr" rid="CR37">37</xref>] showed that different subsets of dendritic cells have different turnover rates, with the myeloid dendritic cells having a faster turnover than the plasmacytoid dendritic cells. However, the plasmacytoid dendritic cells have turnover rates similar to the CD8<inline-formula id="IEq60"><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M86"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq60.gif"/></alternatives></inline-formula> T cells [<xref ref-type="bibr" rid="CR37">37</xref>]. For this reason, throughout this study we consider the baseline <inline-formula id="IEq61"><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M88"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq61.gif"/></alternatives></inline-formula> and <inline-formula id="IEq62"><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M90"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq62.gif"/></alternatives></inline-formula> values defined above. Nevertheless, to describe the heterogeneity of <inline-formula id="IEq63"><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}$$\end{document}</tex-math><mml:math id="M92"><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq63.gif"/></alternatives></inline-formula> population, throughout this study we will vary the rates <inline-formula id="IEq64"><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M94"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq64.gif"/></alternatives></inline-formula> and <inline-formula id="IEq65"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M96"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq65.gif"/></alternatives></inline-formula> over the following parameter ranges: <inline-formula id="IEq66"><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}\in (0.2,3)$$\end{document}</tex-math><mml:math id="M98"><mml:mrow><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq66.gif"/></alternatives></inline-formula>, and <inline-formula id="IEq67"><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}\in (0.2,0.6)$$\end{document}</tex-math><mml:math id="M100"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.2</mml:mn><mml:mo>,</mml:mo><mml:mn>0.6</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq67.gif"/></alternatives></inline-formula>.</p></list-item><list-item><p id="Par24"><italic>IL-7 half life</italic> The IL-7 half-life can range between 6.46 and 9.8&#x000a0;h, depending on the dose [<xref ref-type="bibr" rid="CR38">38</xref>]. This half-life corresponds to an elimination rate between 2.575 and 1.6975/day. Throughout this study we choose a baseline value of <inline-formula id="IEq68"><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}=2.14$$\end{document}</tex-math><mml:math id="M102"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.14</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq68.gif"/></alternatives></inline-formula>/day.</p></list-item><list-item><p id="Par25"><italic>Immune production of IL-7</italic> Since to our knowledge the fraction of IL-7 entering immune vasculature (<inline-formula id="IEq69"><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}$$\end{document}</tex-math><mml:math id="M104"><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq69.gif"/></alternatives></inline-formula>) has not been measured separately, we decided to focus on the overall shedding influx (<inline-formula id="IEq70"><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M106"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq70.gif"/></alternatives></inline-formula>). To this end, we note that [<xref ref-type="bibr" rid="CR18">18</xref>] have estimated that the shedding influx of serum IL-7 in the healthy patients is 10.64 (pg/ml)/<inline-formula id="IEq71"><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{6}$$\end{document}</tex-math><mml:math id="M108"><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq71.gif"/></alternatives></inline-formula>cells/48&#x000a0;h, while the shedding influx of serum IL-7 in ovarian cancer patients is 32.49 (pg/ml)/<inline-formula id="IEq72"><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{6}$$\end{document}</tex-math><mml:math id="M110"><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq72.gif"/></alternatives></inline-formula> cells/48&#x000a0;h. Moreover, the authors hypothesised that the elevated level of IL-7 in the serum and ascites of ovarian cancer patients is mainly from the host immune cells. Thus, we can assume that the shedding influx of IL-7 produced by the immune cells (<inline-formula id="IEq73"><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M112"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq73.gif"/></alternatives></inline-formula>) in ovarian cancer patients is equal to the difference between the shedding influx of IL-7 in the serum of ovarian cancer patients (32.49 pg/ml per <inline-formula id="IEq74"><alternatives><tex-math id="M113">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{6}$$\end{document}</tex-math><mml:math id="M114"><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq74.gif"/></alternatives></inline-formula> cells per 48&#x000a0;h) and that in healthy patients (10.64 pg/ml per <inline-formula id="IEq75"><alternatives><tex-math id="M115">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{6}$$\end{document}</tex-math><mml:math id="M116"><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq75.gif"/></alternatives></inline-formula> cells per 48&#x000a0;h), which equals 21.85 pg/ml per <inline-formula id="IEq76"><alternatives><tex-math id="M117">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{6}$$\end{document}</tex-math><mml:math id="M118"><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq76.gif"/></alternatives></inline-formula> cells per 48&#x000a0;h. Thus, we use a baseline value of <inline-formula id="IEq77"><alternatives><tex-math id="M119">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}=10.925\times 10^{-6}$$\end{document}</tex-math><mml:math id="M120"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>10.925</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq77.gif"/></alternatives></inline-formula> (pg/ml)/cell/day.</p></list-item><list-item><p id="Par26"><italic>Healthy cell production of IL-7</italic> Assuming that the immune cells shed the immune biomarker (IL-7) as a response to tumour formation, then the production of IL-7 in healthy patients (in the absence of any immune responses) can be determined using the steady state mass (<inline-formula id="IEq78"><alternatives><tex-math id="M121">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}^{*}$$\end{document}</tex-math><mml:math id="M122"><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq78.gif"/></alternatives></inline-formula>) of the biomarker: <disp-formula id="Equ6"><alternatives><tex-math id="M123">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\begin{aligned} f_{hi}R_{hi}N_{h}=k_{ei}B_{\text {I}}^{*} \end{aligned}$$\end{document}</tex-math><mml:math id="M124" display="block"><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="12967_2018_1432_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula>
</p><p>The median concentration of IL-7 in healthy control subjects seems to vary between different studies. For example, [<xref ref-type="bibr" rid="CR18">18</xref>] detected a median concentration of serum IL-7 in healthy patients of 10.64&#x000a0;pg/ml. In contrast, [<xref ref-type="bibr" rid="CR14">14</xref>] detected a much lower serum median concentration of IL-7 in healthy patients: 2.9&#x000a0;pg/ml. In the following we consider these high and low serum IL-7 levels for the biomarker steady state <inline-formula id="IEq79"><alternatives><tex-math id="M125">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}^{*}$$\end{document}</tex-math><mml:math id="M126"><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq79.gif"/></alternatives></inline-formula>, and calculate the IL-7 influx as a result of production by the healthy cells:<list list-type="bullet"><list-item><label/><p id="Par27"><italic>High median serum IL-7 concentration</italic> Knowing that the mean plasma volume in a 70-kg female patient is <inline-formula id="IEq80"><alternatives><tex-math id="M127">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{pl}=3150$$\end{document}</tex-math><mml:math id="M128"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3150</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq80.gif"/></alternatives></inline-formula> ml [<xref ref-type="bibr" rid="CR25">25</xref>], we can obtain a baseline value for <inline-formula id="IEq81"><alternatives><tex-math id="M129">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}^{*}=10.64 \times V_{pl}=33516$$\end{document}</tex-math><mml:math id="M130"><mml:mrow><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>10.64</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>33516</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq81.gif"/></alternatives></inline-formula>&#x000a0;pg. For <inline-formula id="IEq82"><alternatives><tex-math id="M131">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}=2.14$$\end{document}</tex-math><mml:math id="M132"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.14</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq82.gif"/></alternatives></inline-formula>, we obtain a baseline influx value of <inline-formula id="IEq83"><alternatives><tex-math id="M133">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{hi}R_{hi}N_{h}=7.16\times 10^{4}$$\end{document}</tex-math><mml:math id="M134"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>7.16</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq83.gif"/></alternatives></inline-formula>&#x000a0;pg/day. Moreover, since <inline-formula id="IEq84"><alternatives><tex-math id="M135">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}\in (1.6975, 2.575/\text {day})$$\end{document}</tex-math><mml:math id="M136"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1.6975</mml:mn><mml:mo>,</mml:mo><mml:mn>2.575</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mtext>day</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq84.gif"/></alternatives></inline-formula>, we obtain that the IL-7 production by healthy cells can vary within the range <inline-formula id="IEq85"><alternatives><tex-math id="M137">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$(5.69\times 10^{4}, 8.63\times 10^{4})$$\end{document}</tex-math><mml:math id="M138"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>5.69</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup><mml:mo>,</mml:mo><mml:mn>8.63</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq85.gif"/></alternatives></inline-formula>&#x000a0;pg/day.</p></list-item><list-item><label/><p id="Par28"><italic>Low median serum IL-7 concentration</italic> In this case we obtain a baseline value for <inline-formula id="IEq86"><alternatives><tex-math id="M139">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}^{*}=2.9\times V_{pl}=9135$$\end{document}</tex-math><mml:math id="M140"><mml:mrow><mml:msubsup><mml:mi>B</mml:mi><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mrow/><mml:mo>&#x02217;</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>2.9</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>9135</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq86.gif"/></alternatives></inline-formula>&#x000a0;pg. For <inline-formula id="IEq87"><alternatives><tex-math id="M141">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}=2.14$$\end{document}</tex-math><mml:math id="M142"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2.14</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq87.gif"/></alternatives></inline-formula>, we obtain a baseline influx value of <inline-formula id="IEq88"><alternatives><tex-math id="M143">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{hi}R_{hi}N_{h}=1.9548\times 10^{4}$$\end{document}</tex-math><mml:math id="M144"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1.9548</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq88.gif"/></alternatives></inline-formula>&#x000a0;pg/day. Moreover, since <inline-formula id="IEq89"><alternatives><tex-math id="M145">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}\in (1.6975, 2.575/\text {day})$$\end{document}</tex-math><mml:math id="M146"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1.6975</mml:mn><mml:mo>,</mml:mo><mml:mn>2.575</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mtext>day</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq89.gif"/></alternatives></inline-formula>, we obtain that the IL-7 production by healthy cells can vary within the range <inline-formula id="IEq90"><alternatives><tex-math id="M147">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$(1.55\times 10^{4}, 2.3522\times 10^{4})$$\end{document}</tex-math><mml:math id="M148"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1.55</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup><mml:mo>,</mml:mo><mml:mn>2.3522</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq90.gif"/></alternatives></inline-formula>&#x000a0;pg/day.</p></list-item></list></p></list-item><list-item><p id="Par29"><italic>Detection and cut-off limits for the immune biomarker assay</italic> In [<xref ref-type="bibr" rid="CR25">25</xref>] the authors considered two threshold values for the detection of CA-125 biomarkers: the detection limit <inline-formula id="IEq91"><alternatives><tex-math id="M149">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{CA125}$$\end{document}</tex-math><mml:math id="M150"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq91.gif"/></alternatives></inline-formula> (defined as the minimum concentration of biomarker detectable in plasma) and the cut-off limit <inline-formula id="IEq92"><alternatives><tex-math id="M151">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M152"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq92.gif"/></alternatives></inline-formula> (defined as the biomarker level that distinguishes a healthy from a disease state). For the detection of median serum IL-7 levels in ovarian cancer patients, [<xref ref-type="bibr" rid="CR18">18</xref>] used a detection range of 0&#x02013;2000 pg/ml with a sensitivity of 10 pg/ml. On the other hand, Mengus et al. [<xref ref-type="bibr" rid="CR39">39</xref>] used a detection limit of 1&#x000a0;pg/ml for IL-7 in prostate cancer. Throughout this study, we use a baseline value of <inline-formula id="IEq93"><alternatives><tex-math id="M153">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{IL7}=1$$\end{document}</tex-math><mml:math id="M154"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq93.gif"/></alternatives></inline-formula> pg/ml. In regard to the cut-off limit of IL-7, [<xref ref-type="bibr" rid="CR14">14</xref>] used a cut-off point of 3.8 pg/ml for IL-7 to distinguish between malignant and benign ovarian tumours (this corresponds to the case of low median IL-7 concentration). On the other hand, for the case of high median IL-7 concentration, [<xref ref-type="bibr" rid="CR18">18</xref>] showed that the 25&#x02013;75&#x02030; for the serum IL-7 levels in patients with ovarian carcinoma are given by the range (13.56&#x02013;54.60)&#x000a0;pg/ml, the 25&#x02013;75&#x02030; in healthy control patients are given by (1.62&#x02013;21.38)&#x000a0;pg/ml, while the 25&#x02013;75&#x02030; in benign control patients are given by (0.07&#x02013;25.73)&#x000a0;pg/ml. Although the authors did not discuss a possible cut-off point, we can assume that this is between 13.5&#x02013;25&#x000a0;pg/ml, with an average of 18 pg/ml. Thus, in this study we will investigate the effect of low and high cut-off points (<inline-formula id="IEq94"><alternatives><tex-math id="M155">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}=3.8$$\end{document}</tex-math><mml:math id="M156"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq94.gif"/></alternatives></inline-formula>, <inline-formula id="IEq95"><alternatives><tex-math id="M157">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}=18$$\end{document}</tex-math><mml:math id="M158"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq95.gif"/></alternatives></inline-formula>), corresponding to both low and high IL-7 serum levels.</p></list-item><list-item><p id="Par30"><italic>Tumor killing rate</italic> We assume that the immune system fails to control tumour growth (due to limited anti-tumour response&#x02014;see [<xref ref-type="bibr" rid="CR19">19</xref>]) and so we use a tumour-killing baseline value of <inline-formula id="IEq96"><alternatives><tex-math id="M159">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}=10^{-6}$$\end{document}</tex-math><mml:math id="M160"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq96.gif"/></alternatives></inline-formula> cells/day. However, to test the sensitivity of the model to this parameter, we perform simulations for <inline-formula id="IEq97"><alternatives><tex-math id="M161">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}\in (10^{-12},10^{-3})$$\end{document}</tex-math><mml:math id="M162"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>12</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq97.gif"/></alternatives></inline-formula>&#x02014;see also Figs. <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig6" ref-type="fig">6</xref>.</p></list-item></list><table-wrap id="Tab1"><label>Table 1</label><caption><p>Description of parameter values involved in the CA-125 dynamics, as given in [<xref ref-type="bibr" rid="CR25">25</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Description (units)</th><th align="left">Baseline value</th></tr></thead><tbody><tr><td align="left">
<inline-formula id="IEq38"><alternatives><tex-math id="M163">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ht}R_{ht}N_{h}$$\end{document}</tex-math><mml:math id="M164"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq38.gif"/></alternatives></inline-formula>
</td><td align="left">Healthy cells shedding influx (U/day)</td><td align="left">
<inline-formula id="IEq39"><alternatives><tex-math id="M165">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$4.56\times 10^{3}$$\end{document}</tex-math><mml:math id="M166"><mml:mrow><mml:mn>4.56</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>3</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq39.gif"/></alternatives></inline-formula>
</td></tr><tr><td align="left">
<inline-formula id="IEq40"><alternatives><tex-math id="M167">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{t}$$\end{document}</tex-math><mml:math id="M168"><mml:msub><mml:mi>f</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq40.gif"/></alternatives></inline-formula>
</td><td align="left">Fraction of tumour biomarker entering tumour vasculature</td><td align="left">0.1</td></tr><tr><td align="left">
<inline-formula id="IEq41"><alternatives><tex-math id="M169">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R_{t}$$\end{document}</tex-math><mml:math id="M170"><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq41.gif"/></alternatives></inline-formula>
</td><td align="left">Biomarker shedding rate per tumour cell (U/day/cell)</td><td align="left">
<inline-formula id="IEq42"><alternatives><tex-math id="M171">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$4.5\times 10^{-5}$$\end{document}</tex-math><mml:math id="M172"><mml:mrow><mml:mn>4.5</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq42.gif"/></alternatives></inline-formula>
</td></tr><tr><td align="left">
<inline-formula id="IEq43"><alternatives><tex-math id="M173">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{h}$$\end{document}</tex-math><mml:math id="M174"><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq43.gif"/></alternatives></inline-formula>
</td><td align="left">The constant level of healthy cells (which shed the CA-125 biomarker) (cell)</td><td align="left">&#x02013;</td></tr><tr><td align="left">
<inline-formula id="IEq44"><alternatives><tex-math id="M175">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M176"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq44.gif"/></alternatives></inline-formula>
</td><td align="left">Growth rate of tumour cell population (day<inline-formula id="IEq45"><alternatives><tex-math id="M177">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{-1}$$\end{document}</tex-math><mml:math id="M178"><mml:msup><mml:mrow/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq45.gif"/></alternatives></inline-formula>)</td><td align="left">
<inline-formula id="IEq46"><alternatives><tex-math id="M179">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$5.78\times 10^{-3}$$\end{document}</tex-math><mml:math id="M180"><mml:mrow><mml:mn>5.78</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq46.gif"/></alternatives></inline-formula>
</td></tr><tr><td align="left">
<inline-formula id="IEq47"><alternatives><tex-math id="M181">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{et}$$\end{document}</tex-math><mml:math id="M182"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">et</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq47.gif"/></alternatives></inline-formula>
</td><td align="left">Elimination rate of tumour biomarker from plasma (day<inline-formula id="IEq48"><alternatives><tex-math id="M183">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{-1}$$\end{document}</tex-math><mml:math id="M184"><mml:msup><mml:mrow/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq48.gif"/></alternatives></inline-formula>)</td><td align="left">0.11</td></tr><tr><td align="left">
<inline-formula id="IEq49"><alternatives><tex-math id="M185">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M186"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq49.gif"/></alternatives></inline-formula>
</td><td align="left">Cut-off limit of CA-125 assay (for healthy vs. disease states), when the biomarker is produced by both tumour and healthy cells (U/ml)</td><td align="left">34.11</td></tr><tr><td align="left">
<inline-formula id="IEq50"><alternatives><tex-math id="M187">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{CA125}$$\end{document}</tex-math><mml:math id="M188"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq50.gif"/></alternatives></inline-formula>
</td><td align="left">Detection limit of CA-125 assay (i.e., min concentration of biomarker detectable in plasma), when the biomarker is produced by the tumour cells alone (U/ml)</td><td align="left">1.5</td></tr><tr><td align="left">
<inline-formula id="IEq51"><alternatives><tex-math id="M189">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{pl}$$\end{document}</tex-math><mml:math id="M190"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq51.gif"/></alternatives></inline-formula>
</td><td align="left">Mean plasma volume in a 70-year female patient (ml)</td><td align="left">3150</td></tr><tr><td align="left">
<inline-formula id="IEq52"><alternatives><tex-math id="M191">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}$$\end{document}</tex-math><mml:math id="M192"><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq52.gif"/></alternatives></inline-formula>
</td><td align="left">Tumour detection time (day)</td><td align="left">To be determined</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Description of parameter values involved in the IL-7 dynamics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Description (units)</th><th align="left">Baseline values</th></tr></thead><tbody><tr><td align="left">
<inline-formula id="IEq183"><alternatives><tex-math id="M193">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M194"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq183.gif"/></alternatives></inline-formula>
</td><td align="left">CD8<inline-formula id="IEq184"><alternatives><tex-math id="M195">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M196"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq184.gif"/></alternatives></inline-formula> T cells doubling time (day<inline-formula id="IEq185"><alternatives><tex-math id="M197">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{-1}$$\end{document}</tex-math><mml:math id="M198"><mml:msup><mml:mrow/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq185.gif"/></alternatives></inline-formula>)</td><td align="left">2.0794</td></tr><tr><td align="left">
<inline-formula id="IEq186"><alternatives><tex-math id="M199">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M200"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq186.gif"/></alternatives></inline-formula>
</td><td align="left">CD8<inline-formula id="IEq187"><alternatives><tex-math id="M201">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M202"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq187.gif"/></alternatives></inline-formula> T cells half-life (day<inline-formula id="IEq188"><alternatives><tex-math id="M203">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{-1}$$\end{document}</tex-math><mml:math id="M204"><mml:msup><mml:mrow/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq188.gif"/></alternatives></inline-formula>)</td><td align="left">0.4</td></tr><tr><td align="left">
<inline-formula id="IEq189"><alternatives><tex-math id="M205">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M206"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq189.gif"/></alternatives></inline-formula>
</td><td align="left">Killing rate of tumour cells by immune effector cells (day<inline-formula id="IEq190"><alternatives><tex-math id="M207">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{-1}$$\end{document}</tex-math><mml:math id="M208"><mml:msup><mml:mrow/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq190.gif"/></alternatives></inline-formula>)</td><td align="left">
<inline-formula id="IEq191"><alternatives><tex-math id="M209">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{-6}$$\end{document}</tex-math><mml:math id="M210"><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq191.gif"/></alternatives></inline-formula>
</td></tr><tr><td align="left">
<inline-formula id="IEq192"><alternatives><tex-math id="M211">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}$$\end{document}</tex-math><mml:math id="M212"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq192.gif"/></alternatives></inline-formula>
</td><td align="left">IL-7 half life (day<inline-formula id="IEq193"><alternatives><tex-math id="M213">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{-1}$$\end{document}</tex-math><mml:math id="M214"><mml:msup><mml:mrow/><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq193.gif"/></alternatives></inline-formula>)</td><td align="left">2.14</td></tr><tr><td align="left">
<italic>M</italic>
</td><td align="left">Carrying capacity of immune cells</td><td align="left">
<inline-formula id="IEq194"><alternatives><tex-math id="M215">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{9}$$\end{document}</tex-math><mml:math id="M216"><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq194.gif"/></alternatives></inline-formula>
</td></tr><tr><td align="left">
<inline-formula id="IEq195"><alternatives><tex-math id="M217">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M218"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq195.gif"/></alternatives></inline-formula>
</td><td align="left">Influx of IL-7 secreted by immune cells, into the vasculature ((pg/ml)/cell/day)</td><td align="left">
<inline-formula id="IEq196"><alternatives><tex-math id="M219">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10.925\times 10^{-6}$$\end{document}</tex-math><mml:math id="M220"><mml:mrow><mml:mn>10.925</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq196.gif"/></alternatives></inline-formula>
</td></tr><tr><td align="left">
<inline-formula id="IEq197"><alternatives><tex-math id="M221">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{hi}R_{hi}N_{h}$$\end{document}</tex-math><mml:math id="M222"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq197.gif"/></alternatives></inline-formula>
</td><td align="left">Healthy cells shedding influx of IL-7 (pg/day)</td><td align="left"><inline-formula id="IEq198"><alternatives><tex-math id="M223">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$1.9548\times 10^{4}$$\end{document}</tex-math><mml:math id="M224"><mml:mrow><mml:mn>1.9548</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq198.gif"/></alternatives></inline-formula> (low shedding); or <inline-formula id="IEq199"><alternatives><tex-math id="M225">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$7.1724\times 10^{4}$$\end{document}</tex-math><mml:math id="M226"><mml:mrow><mml:mn>7.1724</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq199.gif"/></alternatives></inline-formula> (high shedding)</td></tr><tr><td align="left">
<inline-formula id="IEq200"><alternatives><tex-math id="M227">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}$$\end{document}</tex-math><mml:math id="M228"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq200.gif"/></alternatives></inline-formula>
</td><td align="left">Cut-off limit of IL-7 assay (for healthy vs. disease states), when the biomarker is produced by both immune and healthy cells (pg/ml)</td><td align="left">3.8 (low threshold) or 18 (high threshold)</td></tr><tr><td align="left">
<inline-formula id="IEq201"><alternatives><tex-math id="M229">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{IL7}$$\end{document}</tex-math><mml:math id="M230"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq201.gif"/></alternatives></inline-formula>
</td><td align="left">Detection limit of IL-7 assay (i.e., min concentration of IL-7 detectable in plasma), when the biomarker is produced by the immune cells alone (pg/ml)</td><td align="left">1.0</td></tr><tr><td align="left">
<inline-formula id="IEq202"><alternatives><tex-math id="M231">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{pl}$$\end{document}</tex-math><mml:math id="M232"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq202.gif"/></alternatives></inline-formula>
</td><td align="left">Mean plasma volume in a 70-year female patient (ml)</td><td align="left">3150</td></tr><tr><td align="left">
<inline-formula id="IEq203"><alternatives><tex-math id="M233">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M234"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq203.gif"/></alternatives></inline-formula>
</td><td align="left">Tumour detection time based on the CA-125 biomarker (days)</td><td align="left">To be determined</td></tr><tr><td align="left">
<inline-formula id="IEq204"><alternatives><tex-math id="M235">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M236"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq204.gif"/></alternatives></inline-formula>
</td><td align="left">Tumour detection time based on the IL-7 biomarker (days)</td><td align="left">To be determined</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Calculating tumour diameters</title><p id="Par31">To calculate tumour diameters, we assume that a tumour with diameter <inline-formula id="IEq129"><alternatives><tex-math id="M237">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d=1$$\end{document}</tex-math><mml:math id="M238"><mml:mrow><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq129.gif"/></alternatives></inline-formula>&#x000a0;cm contains approximately <inline-formula id="IEq130"><alternatives><tex-math id="M239">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{9}$$\end{document}</tex-math><mml:math id="M240"><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq130.gif"/></alternatives></inline-formula> cells (as suggested in [<xref ref-type="bibr" rid="CR40">40</xref>]). The volume of such a tumour, assumed to be perfectly spherical, is <inline-formula id="IEq131"><alternatives><tex-math id="M241">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{1}=(4/3)\pi (d/2)^{3}=\pi /6$$\end{document}</tex-math><mml:math id="M242"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>4</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>&#x003c0;</mml:mi><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>3</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mi>&#x003c0;</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq131.gif"/></alternatives></inline-formula> (for <inline-formula id="IEq132"><alternatives><tex-math id="M243">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d=1$$\end{document}</tex-math><mml:math id="M244"><mml:mrow><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq132.gif"/></alternatives></inline-formula>&#x000a0;cm). The volume of a tumour with diameter <inline-formula id="IEq133"><alternatives><tex-math id="M245">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{x}$$\end{document}</tex-math><mml:math id="M246"><mml:msub><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq133.gif"/></alternatives></inline-formula>, which contains <italic>x</italic> cells, is <inline-formula id="IEq134"><alternatives><tex-math id="M247">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{d_{x}}=(4/3)\pi (d_{x}/2)^{3}$$\end{document}</tex-math><mml:math id="M248"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>4</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>&#x003c0;</mml:mi><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>3</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq134.gif"/></alternatives></inline-formula>. Using the simple rule of three, we have <inline-formula id="IEq135"><alternatives><tex-math id="M249">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{d_{x}}=x\cdot V_{1}/10^{9}$$\end{document}</tex-math><mml:math id="M250"><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:msub><mml:mo>=</mml:mo><mml:mi>x</mml:mi><mml:mo>&#x000b7;</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq135.gif"/></alternatives></inline-formula>, from which we can obtain the diameter <inline-formula id="IEq136"><alternatives><tex-math id="M251">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{x}$$\end{document}</tex-math><mml:math id="M252"><mml:msub><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq136.gif"/></alternatives></inline-formula> of a tumour containing <italic>x</italic> cells: <inline-formula id="IEq137"><alternatives><tex-math id="M253">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{x}=(x/10^{9})^{1/3}$$\end{document}</tex-math><mml:math id="M254"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq137.gif"/></alternatives></inline-formula>. We will use this formula in Fig. <xref rid="Fig9" ref-type="fig">9</xref>b, to calculate the tumour diameters at the biomarker detection times.</p></sec></sec><sec id="Sec5"><title>Results</title><p id="Par32">To compare our results for the combined use of two cancer biomarkers (i.e., CA-125 and IL-7) with the results in [<xref ref-type="bibr" rid="CR25">25</xref>] for the use of only one cancer biomarker (CA-125), we start in Fig. <xref rid="Fig2" ref-type="fig">2</xref> by showing the time-evolution of tumour cells and the CA-125 biomarker in the absence of any immune response or immune biomarker, under the assumptions that CA-125 can be produced by (b) tumour cells alone, or (c) tumour and healthy cells. (These results are obtained by considering only model (<xref rid="Equ1" ref-type="">1a</xref>), (<xref rid="Equ3" ref-type="">2</xref>), as in [<xref ref-type="bibr" rid="CR25">25</xref>].) In panels (b) and (c) we also show the detection time (<inline-formula id="IEq138"><alternatives><tex-math id="M255">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}$$\end{document}</tex-math><mml:math id="M256"><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq138.gif"/></alternatives></inline-formula>) of the tumour, as calculated by determining the intersection point between the <inline-formula id="IEq139"><alternatives><tex-math id="M257">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M258"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq139.gif"/></alternatives></inline-formula>-curve and the CA-125 detection level <inline-formula id="IEq140"><alternatives><tex-math id="M259">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{CA125}$$\end{document}</tex-math><mml:math id="M260"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq140.gif"/></alternatives></inline-formula> (see panel b), or by determining the intersection point between the <inline-formula id="IEq141"><alternatives><tex-math id="M261">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M262"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq141.gif"/></alternatives></inline-formula>-curve and the CA-125 cut-off level <inline-formula id="IEq142"><alternatives><tex-math id="M263">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M264"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq142.gif"/></alternatives></inline-formula> (see panel c). Note that in panel (a&#x02032;) we also show the size of the tumour at the detection times <inline-formula id="IEq143"><alternatives><tex-math id="M265">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}$$\end{document}</tex-math><mml:math id="M266"><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq143.gif"/></alternatives></inline-formula> corresponding to the two cases shown in panels (b) and (c).<fig id="Fig2"><label>Fig. 2</label><caption><p>The dynamics of tumour cells and tumour biomarkers in the absence of any immune response (i.e., <inline-formula id="IEq32"><alternatives><tex-math id="M267">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}=B_{\text {I}}=0$$\end{document}</tex-math><mml:math id="M268"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq32.gif"/></alternatives></inline-formula>), as investigated in [<xref ref-type="bibr" rid="CR25">25</xref>]: <bold>a</bold> time-evolution of ovarian cancer cells; <bold>a&#x02032;</bold> tumour size (cell numbers) at the detection times <inline-formula id="IEq33"><alternatives><tex-math id="M269">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}$$\end{document}</tex-math><mml:math id="M270"><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq33.gif"/></alternatives></inline-formula>, when the CA-125 biomarkers reach the detection thresholds (as shown in <bold>b</bold>, <bold>c</bold>); <bold>b</bold> dynamics of CA-125 biomarker, when we assume only tumour shedding. Horizontal line shows the biomarker detection threshold <inline-formula id="IEq34"><alternatives><tex-math id="M271">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{CA125}$$\end{document}</tex-math><mml:math id="M272"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq34.gif"/></alternatives></inline-formula>. In this case, the tumour detection threshold is <inline-formula id="IEq35"><alternatives><tex-math id="M273">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}=8.8$$\end{document}</tex-math><mml:math id="M274"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq35.gif"/></alternatives></inline-formula> years; see also [<xref ref-type="bibr" rid="CR25">25</xref>]; <bold>c</bold> dynamics of CA-125 biomarker, when we assume both tumour and healthy cells shedding. Horizontal line shows the biomarker cut-off threshold <inline-formula id="IEq36"><alternatives><tex-math id="M275">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M276"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq36.gif"/></alternatives></inline-formula>. In this case, the tumour detection threshold is <inline-formula id="IEq37"><alternatives><tex-math id="M277">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}=10.1$$\end{document}</tex-math><mml:math id="M278"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>10.1</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq37.gif"/></alternatives></inline-formula>&#x000a0;years; see also [<xref ref-type="bibr" rid="CR25">25</xref>]. The parameter values for these simulations are given in Table <xref rid="Tab1" ref-type="table">1</xref></p></caption><graphic xlink:href="12967_2018_1432_Fig2_HTML" id="MO6"/></fig></p><p id="Par33">In Fig. <xref rid="Fig3" ref-type="fig">3</xref> we show the time evolution of tumour cells, immune cells, and tumour and immune biomarkers for the baseline parameter values listed in Table <xref rid="Tab2" ref-type="table">2</xref>, corresponding to <italic>low IL-7 serum baseline levels</italic> (i.e., <inline-formula id="IEq144"><alternatives><tex-math id="M279">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{hi}R_{hi}N_{h}=1.9548\times 10^{4}$$\end{document}</tex-math><mml:math id="M280"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">hi</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1.9548</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq144.gif"/></alternatives></inline-formula>, <inline-formula id="IEq145"><alternatives><tex-math id="M281">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}=3.8$$\end{document}</tex-math><mml:math id="M282"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq145.gif"/></alternatives></inline-formula>). We note that when the immune response is included, but we assume that IL-7 is produced only by the immune cells and CA-125 is produced only by tumour cells, then the tumour detection time based on CA-125 (<inline-formula id="IEq146"><alternatives><tex-math id="M283">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}=8.8$$\end{document}</tex-math><mml:math id="M284"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq146.gif"/></alternatives></inline-formula> years) is lower than the tumour detection time based on IL-7 (<inline-formula id="IEq147"><alternatives><tex-math id="M285">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}=9.27$$\end{document}</tex-math><mml:math id="M286"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>9.27</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq147.gif"/></alternatives></inline-formula>&#x000a0;years); see panels a&#x02032;, b&#x02032;. However, when we assume that the tumour and immune biomarkers are produced also by the healthy cells in the environment, then <inline-formula id="IEq148"><alternatives><tex-math id="M287">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}=10.07&#x0003e;D_{T}^{i}=9.15$$\end{document}</tex-math><mml:math id="M288"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>10.07</mml:mn><mml:mo>&#x0003e;</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>9.15</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq148.gif"/></alternatives></inline-formula>. Hence, the inclusion of the serum cytokine concentration in the detection tests for ovarian cancer, could lead to earlier detection of the tumour mass (i.e., almost 1&#x000a0;year earlier).<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>a</bold> Time-evolution of tumour cell population; <bold>b</bold> time-evolution of immune cell population; time-evolution of tumour biomarkers secreted by tumour cells alone (<bold>a&#x02032;</bold>) or by tumour and healthy cells (<bold>a&#x02033;</bold>); time-evolution of immune biomarkers secreted by immune cells alone (<bold>b&#x02032;</bold>) or by immune and healthy cells (<bold>b&#x02033;</bold>); <bold>c&#x02032;</bold>, <bold>c&#x02033;</bold> tumour size at the detection times <inline-formula id="IEq98"><alternatives><tex-math id="M289">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M290"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq98.gif"/></alternatives></inline-formula> and <inline-formula id="IEq99"><alternatives><tex-math id="M291">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M292"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq99.gif"/></alternatives></inline-formula> (corresponding to <bold>a&#x02032;</bold>, <bold>b&#x02032;</bold>, and <bold>a&#x02033;</bold>, <bold>b&#x02033;</bold> respectively). Parameter values for these simulations are given in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>. The dotted horizontal lines in <bold>a&#x02032;</bold>, <bold>b&#x02032;</bold> show detection thresholds for CA-125 and IL-7 calculated by multiplying <inline-formula id="IEq100"><alternatives><tex-math id="M293">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{CA125}$$\end{document}</tex-math><mml:math id="M294"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq100.gif"/></alternatives></inline-formula> and <inline-formula id="IEq101"><alternatives><tex-math id="M295">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{IL7}$$\end{document}</tex-math><mml:math id="M296"><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq101.gif"/></alternatives></inline-formula> with <inline-formula id="IEq102"><alternatives><tex-math id="M297">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{pl}$$\end{document}</tex-math><mml:math id="M298"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq102.gif"/></alternatives></inline-formula> = the mean plasma volume in a 70-kg female patient. The dotted horizontal lines in panels <bold>a&#x02033;</bold>, <bold>b&#x02033;</bold> show cut-off thresholds for CA-125 and IL-7 calculated by multiplying <inline-formula id="IEq103"><alternatives><tex-math id="M299">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M300"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq103.gif"/></alternatives></inline-formula> and <inline-formula id="IEq104"><alternatives><tex-math id="M301">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}$$\end{document}</tex-math><mml:math id="M302"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq104.gif"/></alternatives></inline-formula> with <inline-formula id="IEq105"><alternatives><tex-math id="M303">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$V_{pl}$$\end{document}</tex-math><mml:math id="M304"><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi mathvariant="italic">pl</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq105.gif"/></alternatives></inline-formula></p></caption><graphic xlink:href="12967_2018_1432_Fig3_HTML" id="MO8"/></fig>
</p><p id="Par34">In Fig. <xref rid="Fig4" ref-type="fig">4</xref> we have also briefly investigated the effect of having <italic>higher baseline serum IL-7 levels</italic> (as in [<xref ref-type="bibr" rid="CR18">18</xref>]). The results show that for lower immune carrying capacity values (i.e., <inline-formula id="IEq149"><alternatives><tex-math id="M305">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$M=10^{9}$$\end{document}</tex-math><mml:math id="M306"><mml:mrow><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq149.gif"/></alternatives></inline-formula>), the level of immune cells in the system does not produce enough IL-7 to be detected above the cut-off threshold of 18&#x000a0;pg/ml. (Since there are no changes in the evolution of <inline-formula id="IEq150"><alternatives><tex-math id="M307">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M308"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq150.gif"/></alternatives></inline-formula>, <inline-formula id="IEq151"><alternatives><tex-math id="M309">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}(t)$$\end{document}</tex-math><mml:math id="M310"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq151.gif"/></alternatives></inline-formula> or <inline-formula id="IEq152"><alternatives><tex-math id="M311">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M312"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq152.gif"/></alternatives></inline-formula> compared to Fig. <xref rid="Fig3" ref-type="fig">3</xref>, we do not show here the dynamics of these variables.) To be able to detect between healthy and cancerous states it is necessary to either assume that there are more immune cells in the system (i.e., higher carrying capacity: <inline-formula id="IEq153"><alternatives><tex-math id="M313">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$M=10^{10}$$\end{document}</tex-math><mml:math id="M314"><mml:mrow><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>10</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq153.gif"/></alternatives></inline-formula>; see panel b) or higher secretion rate of IL-7 by the existent immune cells (i.e., higher <inline-formula id="IEq154"><alternatives><tex-math id="M315">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M316"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq154.gif"/></alternatives></inline-formula>&#x02014;but we do not have any data to suggest these higher secretion values).</p><p id="Par35">Since the heterogeneity of the immune response [<xref ref-type="bibr" rid="CR41">41</xref>] can lead to small variations in the immune parameters, in the following we investigate how changes in the parameters associated with the immune response affect the tumour detection time. To this end, we focus only on the case of low baseline serum IL-7 (corresponding to the clinical data in [<xref ref-type="bibr" rid="CR14">14</xref>]).<fig id="Fig4"><label>Fig. 4</label><caption><p>The time-evolution of immune biomarker concentration, for higher baseline IL-7 serum levels (i.e. <inline-formula id="IEq106"><alternatives><tex-math id="M317">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}=18$$\end{document}</tex-math><mml:math id="M318"><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq106.gif"/></alternatives></inline-formula>), as we increase the carrying capacity of immune cells (to allow the cells to reach higher numbers); <bold>a</bold>
<inline-formula id="IEq107"><alternatives><tex-math id="M319">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$M=10^{9}$$\end{document}</tex-math><mml:math id="M320"><mml:mrow><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq107.gif"/></alternatives></inline-formula>; <bold>b</bold>
<inline-formula id="IEq108"><alternatives><tex-math id="M321">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$M=10^{10}$$\end{document}</tex-math><mml:math id="M322"><mml:mrow><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>10</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq108.gif"/></alternatives></inline-formula></p></caption><graphic xlink:href="12967_2018_1432_Fig4_HTML" id="MO9"/></fig>
</p><sec id="Sec6"><title>Tumour detection times as we vary immune and tumour parameters</title><p id="Par36">Figure <xref rid="Fig5" ref-type="fig">5</xref> shows the detection times <inline-formula id="IEq155"><alternatives><tex-math id="M323">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M324"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq155.gif"/></alternatives></inline-formula> and <inline-formula id="IEq156"><alternatives><tex-math id="M325">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M326"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq156.gif"/></alternatives></inline-formula> for the tumour and immune biomarkers, as we vary: (a) the tumour elimination rate <inline-formula id="IEq157"><alternatives><tex-math id="M327">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M328"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq157.gif"/></alternatives></inline-formula>; (b) the immune activation/proliferation rate <inline-formula id="IEq158"><alternatives><tex-math id="M329">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M330"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq158.gif"/></alternatives></inline-formula>; (c) the half-life of immune cells <inline-formula id="IEq159"><alternatives><tex-math id="M331">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M332"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq159.gif"/></alternatives></inline-formula>; (d) the carrying capacity of immune cells <italic>M</italic>; (e) the half-saturation constant for the anti-tumour immune response <inline-formula id="IEq160"><alternatives><tex-math id="M333">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$h_{i}$$\end{document}</tex-math><mml:math id="M334"><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq160.gif"/></alternatives></inline-formula>; (f) the degradation rate <inline-formula id="IEq161"><alternatives><tex-math id="M335">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}$$\end{document}</tex-math><mml:math id="M336"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq161.gif"/></alternatives></inline-formula> of the immune biomarker; (g) the influx rate <inline-formula id="IEq162"><alternatives><tex-math id="M337">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M338"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq162.gif"/></alternatives></inline-formula> of IL-7 that is secreted by immune cells. First, we note that variations in the half-saturation constant <inline-formula id="IEq163"><alternatives><tex-math id="M339">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$h_{i}$$\end{document}</tex-math><mml:math id="M340"><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq163.gif"/></alternatives></inline-formula> does not have any effect on the detection times (see Fig. <xref rid="Fig5" ref-type="fig">5</xref>e). Second, we note that variations in almost all other parameters can lead to an interchange between the time <inline-formula id="IEq164"><alternatives><tex-math id="M341">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M342"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq164.gif"/></alternatives></inline-formula> when the tumour biomarker reaches its cut-off threshold <inline-formula id="IEq165"><alternatives><tex-math id="M343">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M344"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq165.gif"/></alternatives></inline-formula> and the time <inline-formula id="IEq166"><alternatives><tex-math id="M345">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M346"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq166.gif"/></alternatives></inline-formula> the immune biomarker reaches its cut-off threshold <inline-formula id="IEq167"><alternatives><tex-math id="M347">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}$$\end{document}</tex-math><mml:math id="M348"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq167.gif"/></alternatives></inline-formula> (see Fig. <xref rid="Fig5" ref-type="fig">5</xref>b, d, f, g). For the baseline parameter values listed in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>, we have <inline-formula id="IEq168"><alternatives><tex-math id="M349">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}&#x0003c;D_{T}^{t}$$\end{document}</tex-math><mml:math id="M350"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mo>&#x0003c;</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq168.gif"/></alternatives></inline-formula>, suggesting that the immune response could be used to improve the overall tumour detection time. Some of these interchanges in the tumour/immune biomarkers detection times occur outside realistic parameter ranges (e.g., <inline-formula id="IEq169"><alternatives><tex-math id="M351">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}\in (1.6975,2.575)$$\end{document}</tex-math><mml:math id="M352"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1.6975</mml:mn><mml:mo>,</mml:mo><mml:mn>2.575</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq169.gif"/></alternatives></inline-formula> as in [<xref ref-type="bibr" rid="CR38">38</xref>], but in Fig. <xref rid="Fig5" ref-type="fig">5</xref>f we investigated the range <inline-formula id="IEq170"><alternatives><tex-math id="M353">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}\in (1,3.5)$$\end{document}</tex-math><mml:math id="M354"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02208;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>3.5</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq170.gif"/></alternatives></inline-formula>). However, they can inform us of possible dynamics in perturbed system (e.g., following immunotherapies for different diseases&#x02014;other than cancer, which might affect also the immune response to cancer and the cancer detection times).<fig id="Fig5"><label>Fig. 5</label><caption><p>The effect of changing various immune-related parameters, namely <bold>a</bold>
<inline-formula id="IEq109"><alternatives><tex-math id="M355">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M356"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq109.gif"/></alternatives></inline-formula>, <bold>b</bold>
<inline-formula id="IEq110"><alternatives><tex-math id="M357">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M358"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq110.gif"/></alternatives></inline-formula>, <bold>c</bold>
<inline-formula id="IEq111"><alternatives><tex-math id="M359">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M360"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq111.gif"/></alternatives></inline-formula>, <bold>d</bold>
<italic>M</italic>, <bold>e</bold>
<inline-formula id="IEq112"><alternatives><tex-math id="M361">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$h_{i}$$\end{document}</tex-math><mml:math id="M362"><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq112.gif"/></alternatives></inline-formula>, <bold>f</bold>
<inline-formula id="IEq113"><alternatives><tex-math id="M363">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}$$\end{document}</tex-math><mml:math id="M364"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq113.gif"/></alternatives></inline-formula>, <bold>g</bold>
<inline-formula id="IEq114"><alternatives><tex-math id="M365">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M366"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq114.gif"/></alternatives></inline-formula>, on the cancer detection times calculated based on the cut-off thresholds for the tumour biomarkers (<inline-formula id="IEq115"><alternatives><tex-math id="M367">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M368"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq115.gif"/></alternatives></inline-formula>; blue circles) and the immune biomarkers (<inline-formula id="IEq116"><alternatives><tex-math id="M369">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M370"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq116.gif"/></alternatives></inline-formula>; red diamonds). The vertical dashed lines denote the baseline parameter values, as listed in Table <xref rid="Tab2" ref-type="table">2</xref></p></caption><graphic xlink:href="12967_2018_1432_Fig5_HTML" id="MO10"/></fig></p><p id="Par37">We note in Fig. <xref rid="Fig5" ref-type="fig">5</xref> that with the exception of changes in <inline-formula id="IEq171"><alternatives><tex-math id="M371">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M372"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq171.gif"/></alternatives></inline-formula>, changes in all other immune-related parameters do not seem to affect the tumour detection time <inline-formula id="IEq172"><alternatives><tex-math id="M373">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M374"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq172.gif"/></alternatives></inline-formula> based on the CA-125 biomarker (such changes affect only <inline-formula id="IEq173"><alternatives><tex-math id="M375">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M376"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq173.gif"/></alternatives></inline-formula>). The reason for this result is the very low tumour killing rate <inline-formula id="IEq174"><alternatives><tex-math id="M377">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M378"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq174.gif"/></alternatives></inline-formula> (which was assumed at a baseline value of <inline-formula id="IEq175"><alternatives><tex-math id="M379">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{-6}$$\end{document}</tex-math><mml:math id="M380"><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq175.gif"/></alternatives></inline-formula>/day&#x02014;to explain the failure in the immune response to control tumour growth). Increasing this tumour killing rate could lead to small changes in <inline-formula id="IEq176"><alternatives><tex-math id="M381">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M382"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq176.gif"/></alternatives></inline-formula>, as shown in Fig. <xref rid="Fig6" ref-type="fig">6</xref> (for different <inline-formula id="IEq177"><alternatives><tex-math id="M383">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M384"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq177.gif"/></alternatives></inline-formula> and <inline-formula id="IEq178"><alternatives><tex-math id="M385">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M386"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq178.gif"/></alternatives></inline-formula> values). However, higher <inline-formula id="IEq179"><alternatives><tex-math id="M387">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M388"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq179.gif"/></alternatives></inline-formula> values also mean that tumours can be detected much later.<fig id="Fig6"><label>Fig. 6</label><caption><p>Tumour detection times, <inline-formula id="IEq117"><alternatives><tex-math id="M389">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M390"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq117.gif"/></alternatives></inline-formula> and <inline-formula id="IEq118"><alternatives><tex-math id="M391">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M392"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq118.gif"/></alternatives></inline-formula> for higher tumour lysis rate <inline-formula id="IEq119"><alternatives><tex-math id="M393">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}=5\times 10^{-4}$$\end{document}</tex-math><mml:math id="M394"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq119.gif"/></alternatives></inline-formula>, as we vary two immune parameters: <bold>a</bold>
<inline-formula id="IEq120"><alternatives><tex-math id="M395">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M396"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq120.gif"/></alternatives></inline-formula> and <bold>b</bold>
<inline-formula id="IEq121"><alternatives><tex-math id="M397">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{i}$$\end{document}</tex-math><mml:math id="M398"><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq121.gif"/></alternatives></inline-formula></p></caption><graphic xlink:href="12967_2018_1432_Fig6_HTML" id="MO11"/></fig>
</p><p id="Par38">Finally, in Fig. <xref rid="Fig7" ref-type="fig">7</xref> we show the effects of varying tumour-related parameters on tumour detection times <inline-formula id="IEq180"><alternatives><tex-math id="M399">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M400"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq180.gif"/></alternatives></inline-formula> and <inline-formula id="IEq181"><alternatives><tex-math id="M401">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M402"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq181.gif"/></alternatives></inline-formula>. We remark in panel (a) that changes in tumour proliferation rate <inline-formula id="IEq182"><alternatives><tex-math id="M403">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M404"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq182.gif"/></alternatives></inline-formula> affect both tumour and immune biomarker levels, which subsequently affect the tumour detection times. In contrast, changes in all other tumour-related parameters affect only the tumour biomarkers.<fig id="Fig7"><label>Fig. 7</label><caption><p>The effect of changing various tumour-related parameters, namely <bold>a</bold>
<inline-formula id="IEq122"><alternatives><tex-math id="M405">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M406"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq122.gif"/></alternatives></inline-formula>, <bold>b</bold>
<inline-formula id="IEq123"><alternatives><tex-math id="M407">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{ht}R_{ht}N_{h}$$\end{document}</tex-math><mml:math id="M408"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi mathvariant="italic">ht</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>N</mml:mi><mml:mi>h</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq123.gif"/></alternatives></inline-formula>, <bold>c</bold>
<inline-formula id="IEq124"><alternatives><tex-math id="M409">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{t}$$\end{document}</tex-math><mml:math id="M410"><mml:msub><mml:mi>f</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq124.gif"/></alternatives></inline-formula>, <bold>d</bold>
<inline-formula id="IEq125"><alternatives><tex-math id="M411">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R_{t}$$\end{document}</tex-math><mml:math id="M412"><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq125.gif"/></alternatives></inline-formula>, <bold>e</bold>
<inline-formula id="IEq126"><alternatives><tex-math id="M413">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{et}$$\end{document}</tex-math><mml:math id="M414"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">et</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq126.gif"/></alternatives></inline-formula>, on the cancer detection times calculated based on the cut-off thresholds for the tumour biomarkers (<inline-formula id="IEq127"><alternatives><tex-math id="M415">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M416"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq127.gif"/></alternatives></inline-formula>; blue circles) and the immune biomarkers (<inline-formula id="IEq128"><alternatives><tex-math id="M417">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M418"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq128.gif"/></alternatives></inline-formula>; red diamonds). The vertical dashed lines denote the baseline parameter values, as listed in Table <xref rid="Tab1" ref-type="table">1</xref></p></caption><graphic xlink:href="12967_2018_1432_Fig7_HTML" id="MO12"/></fig>
</p></sec><sec id="Sec7"><title>Tumour size at detection time</title><p id="Par39">
To investigate the size of the tumour at the detection time, in Fig. <xref rid="Fig8" ref-type="fig">8</xref> we show <inline-formula id="IEq207"><alternatives><tex-math id="M419">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M420"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq207.gif"/></alternatives></inline-formula> at times <inline-formula id="IEq208"><alternatives><tex-math id="M421">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t=D_{T}^{t}$$\end{document}</tex-math><mml:math id="M422"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq208.gif"/></alternatives></inline-formula> (blue circles) and <inline-formula id="IEq209"><alternatives><tex-math id="M423">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t=D_{T}^{i}$$\end{document}</tex-math><mml:math id="M424"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq209.gif"/></alternatives></inline-formula> (red diamonds). We note that for the majority of parameters the tumour size increases/decreases as we vary the parameters, in the same manner as the tumour detection times increase/decrease as we vary these parameters&#x02014;see also Figs. <xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig7" ref-type="fig">7</xref>. It is worth mentioning here that by varying some immune parameters, one could detect even very small tumours (e.g., tumours less than <inline-formula id="IEq210"><alternatives><tex-math id="M425">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{7}$$\end{document}</tex-math><mml:math id="M426"><mml:msup><mml:mn>10</mml:mn><mml:mn>7</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq210.gif"/></alternatives></inline-formula> cells&#x02014;see Fig. <xref rid="Fig8" ref-type="fig">8</xref>f, g).<fig id="Fig8"><label>Fig. 8</label><caption><p>Tumour size at the detection times <inline-formula id="IEq205"><alternatives><tex-math id="M427">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M428"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq205.gif"/></alternatives></inline-formula> (blue circles) and <inline-formula id="IEq206"><alternatives><tex-math id="M429">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M430"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq206.gif"/></alternatives></inline-formula> (red diamonds), as we vary: <bold>a</bold>&#x02013;<bold>g</bold> the immune parameters corresponding to a&#x02013;g in Fig. <xref rid="Fig5" ref-type="fig">5</xref>; and <bold>h</bold> the tumour growth rate, corresponding to Fig. <xref rid="Fig7" ref-type="fig">7</xref>a</p></caption><graphic xlink:href="12967_2018_1432_Fig8_HTML" id="MO13"/></fig>
</p><p id="Par41">There is one particular aspect that we need to emphasise in Fig. <xref rid="Fig8" ref-type="fig">8</xref>: changes in parameters <inline-formula id="IEq211"><alternatives><tex-math id="M431">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M432"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq211.gif"/></alternatives></inline-formula> and <inline-formula id="IEq212"><alternatives><tex-math id="M433">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M434"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq212.gif"/></alternatives></inline-formula> do not lead to changes in tumour size at detection times (for either <inline-formula id="IEq213"><alternatives><tex-math id="M435">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M436"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq213.gif"/></alternatives></inline-formula> or <inline-formula id="IEq214"><alternatives><tex-math id="M437">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M438"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq214.gif"/></alternatives></inline-formula>). This is in contrast with the effects of <inline-formula id="IEq215"><alternatives><tex-math id="M439">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M440"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq215.gif"/></alternatives></inline-formula> and <inline-formula id="IEq216"><alternatives><tex-math id="M441">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M442"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq216.gif"/></alternatives></inline-formula> on the detection times (see Figs. <xref rid="Fig5" ref-type="fig">5</xref>a, <xref rid="Fig7" ref-type="fig">7</xref>a).</p></sec><sec id="Sec8"><title>Predictions of tumour evolution in the (IL-7, CA-125) phase space</title><p id="Par42">Finally, we discuss our results in the context of diagnosing ovarian cancer in the (IL-7, CA-125) variables space. We note that [<xref ref-type="bibr" rid="CR14">14</xref>] investigated the levels of IL-7 and CA-125 that can be used to predict benign versus malignant ovarian tumours&#x02014;see also Fig. <xref rid="Fig9" ref-type="fig">9</xref>a. In this figure we observe that for low CA-125 (<inline-formula id="IEq217"><alternatives><tex-math id="M443">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003c;40$$\end{document}</tex-math><mml:math id="M444"><mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mn>40</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq217.gif"/></alternatives></inline-formula>), a reduced IL-7 level (<inline-formula id="IEq218"><alternatives><tex-math id="M445">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003c;3.8$$\end{document}</tex-math><mml:math id="M446"><mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq218.gif"/></alternatives></inline-formula>) predicted 22% of malignant cases, while an increased IL-7 level (<inline-formula id="IEq219"><alternatives><tex-math id="M447">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003e;3.8$$\end{document}</tex-math><mml:math id="M448"><mml:mrow><mml:mo>&#x0003e;</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq219.gif"/></alternatives></inline-formula>) predicted only 9% of malignant cases (despite the fact that malignant ovarian cancers are usually associated with higher IL-7 levels); see [<xref ref-type="bibr" rid="CR14">14</xref>]. This discrepancy in the predictions could be the effect of low specificity and sensitivity of IL-7 [<xref ref-type="bibr" rid="CR14">14</xref>], which is related to the multiple roles of IL-7 in the homeostasis of the immune system [<xref ref-type="bibr" rid="CR42">42</xref>]. We will discuss this aspect in more detail in the next section.<fig id="Fig9"><label>Fig. 9</label><caption><p><bold>a</bold> Regions of malignant vs. benign tumour predictions in the (IL-7, CA-125) parameter space, as proposed in the clinical study by [<xref ref-type="bibr" rid="CR14">14</xref>]. <bold>b</bold>(<bold>i</bold>) Regions of healthy vs. cancerous states in the (IL-7, CA-125) phase plane, as predicted by the numerical simulations; (<bold>ii</bold>) tumour size versus the immune biomarker (IL-7) level (the dotted vertical line shows the IL-7 detection threshold, while the dashed horizontal line shows tumour size at the detection time); (<bold>iii</bold>) tumour size versus the cancer biomarker (CA-125) level (the dotted horizontal line shows the CA-125 detection threshold, while the dashed vertical line shows tumour size at the detection time). The blue arrows on the solution curves show the increase in time</p></caption><graphic xlink:href="12967_2018_1432_Fig9_HTML" id="MO14"/></fig></p><p id="Par43">Since our mathematical model does not distinguish between malignant and benign tumours, but rather the healthy from the cancerous states, in Fig. <xref rid="Fig9" ref-type="fig">9</xref>b(i) we graph <inline-formula id="IEq220"><alternatives><tex-math id="M449">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}(t)$$\end{document}</tex-math><mml:math id="M450"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq220.gif"/></alternatives></inline-formula> versus <inline-formula id="IEq221"><alternatives><tex-math id="M451">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {T}}(t)$$\end{document}</tex-math><mml:math id="M452"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq221.gif"/></alternatives></inline-formula> and their cut-off thresholds. First we note that the &#x0201c;healthy&#x0201d; state is characterised by CA-125 <inline-formula id="IEq222"><alternatives><tex-math id="M453">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003c;15$$\end{document}</tex-math><mml:math id="M454"><mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mn>15</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq222.gif"/></alternatives></inline-formula> U/ml, which is consistent with clinical data on healthy control patients&#x02014;see Table <xref rid="Tab2" ref-type="table">2</xref> in [<xref ref-type="bibr" rid="CR14">14</xref>]. Second, for <inline-formula id="IEq223"><alternatives><tex-math id="M455">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t&#x0003e;D_{T}^{t}$$\end{document}</tex-math><mml:math id="M456"><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq223.gif"/></alternatives></inline-formula> the tumour is detected through elevated tumour biomarkers and the &#x0201c;cancerous&#x0201d; state is characterised by CA-125 <inline-formula id="IEq224"><alternatives><tex-math id="M457">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003e;35$$\end{document}</tex-math><mml:math id="M458"><mml:mrow><mml:mo>&#x0003e;</mml:mo><mml:mn>35</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq224.gif"/></alternatives></inline-formula> U/ml. The region with CA-125 <inline-formula id="IEq225"><alternatives><tex-math id="M459">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003c;35$$\end{document}</tex-math><mml:math id="M460"><mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mn>35</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq225.gif"/></alternatives></inline-formula> and IL-7 <inline-formula id="IEq226"><alternatives><tex-math id="M461">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003e;3.8$$\end{document}</tex-math><mml:math id="M462"><mml:mrow><mml:mo>&#x0003e;</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq226.gif"/></alternatives></inline-formula> could be characterised by either a &#x0201c;healthy&#x0201d; or &#x0201c;cancerous&#x0201d; state, since up to 22% of cancerous patients have shown to exhibit lower CA-125 values [<xref ref-type="bibr" rid="CR9">9</xref>] (and in fact, more recent CA-125 assays now accept a cut-off limit of 20 U/ml [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]). For the parameter values used in this study (see Table <xref rid="Tab1" ref-type="table">1</xref>), the dynamics of system (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>) did not enter the space region characterised by <inline-formula id="IEq227"><alternatives><tex-math id="M463">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}}(t)&#x0003c;3.8$$\end{document}</tex-math><mml:math id="M464"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq227.gif"/></alternatives></inline-formula> and <inline-formula id="IEq228"><alternatives><tex-math id="M465">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {T}}(t)&#x0003e;35$$\end{document}</tex-math><mml:math id="M466"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>&#x0003e;</mml:mo><mml:mn>35</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq228.gif"/></alternatives></inline-formula>; although [<xref ref-type="bibr" rid="CR14">14</xref>] showed that there are clinical cases of malignant cancer in this region, as seen in panel (a). Such numerical results could be obtained for example for very low <inline-formula id="IEq229"><alternatives><tex-math id="M467">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M468"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq229.gif"/></alternatives></inline-formula>, <italic>M</italic> or <inline-formula id="IEq230"><alternatives><tex-math id="M469">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M470"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq230.gif"/></alternatives></inline-formula> values, when <inline-formula id="IEq231"><alternatives><tex-math id="M471">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}&#x0003c;D_{T}^{i}$$\end{document}</tex-math><mml:math id="M472"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup><mml:mo>&#x0003c;</mml:mo><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq231.gif"/></alternatives></inline-formula> (as shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par44">Because the aim of this study is to investigate whether the addition of an immune biomarker could be used to improve early cancer detection, in Fig. <xref rid="Fig9" ref-type="fig">9</xref>b(ii), (iii) we graph tumour size versus the two biomarkers (IL-7 and CA-125), together with the tumour diameters at the detection times. (We explained how we calculated these diameters in &#x0201c;<xref rid="Sec2" ref-type="sec">Methods</xref>&#x0201d; section.) Overall, these results suggest that by considering also immune biomarkers, we could detect tumours that have much smaller sizes: e.g., diameters of <inline-formula id="IEq232"><alternatives><tex-math id="M473">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\approx 0.62$$\end{document}</tex-math><mml:math id="M474"><mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>0.62</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq232.gif"/></alternatives></inline-formula>&#x000a0;cm, as showed in Fig. <xref rid="Fig9" ref-type="fig">9</xref>b(ii). Moreover, lower tumours could be detected if different immune-related model parameters are varied (as shown in Figs. <xref rid="Fig5" ref-type="fig">5</xref>, <xref rid="Fig7" ref-type="fig">7</xref>a; and as supported by the heterogeneity of the immune response [<xref ref-type="bibr" rid="CR41">41</xref>]). As we will discuss in more detail in the next section, this result could fall within the remits of the study in [<xref ref-type="bibr" rid="CR44">44</xref>], which suggested that the detection sensitivity could increase to <inline-formula id="IEq233"><alternatives><tex-math id="M475">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\approx 80\%$$\end{document}</tex-math><mml:math id="M476"><mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>80</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq233.gif"/></alternatives></inline-formula> for tumours of <inline-formula id="IEq234"><alternatives><tex-math id="M477">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\approx 0.5$$\end{document}</tex-math><mml:math id="M478"><mml:mrow><mml:mo>&#x02248;</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq234.gif"/></alternatives></inline-formula>&#x000a0;cm diameters.</p></sec></sec><sec id="Sec9"><title>Discussion</title><p id="Par45">Improving the current methods of tumour detection is a critical question in tumour research. A few years ago, [<xref ref-type="bibr" rid="CR25">25</xref>] proposed a simple mathematical model to predict tumour detection times based on the level of tumour biomarkers. Applying the model to ovarian tumours and the CA-125 biomarkers, the authors concluded that this type of tumour could grow undetected at least 8.8&#x02013;10.1&#x000a0;years (from the moment the tumour starts forming). However, what the authors did not consider in their study is the immunogenicity of the tumours, especially since the epithelial ovarian cancers have been shown to be quite immunogenic [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par46">In this study we proposed a new mathematical model that described the interactions between tumour and immune cells, and the secretion of tumour biomarkers (CA-125) and immune biomarkers (IL-7) that could be both used to predict the presence of ovarian tumours.</p><p id="Par47">Using this model, we showed that by combining tumour and immune biomarkers one can either increase or reduce the time for tumour detection, depending on whether the biomarkers are produced also by healthy cells. For example, assuming that CA-125 is produced only by cancer cells and IL-7 is produced only by immune cells lead to detection times <inline-formula id="IEq235"><alternatives><tex-math id="M479">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}=8.8$$\end{document}</tex-math><mml:math id="M480"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>8.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq235.gif"/></alternatives></inline-formula> years and <inline-formula id="IEq236"><alternatives><tex-math id="M481">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}=9.27$$\end{document}</tex-math><mml:math id="M482"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>9.27</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq236.gif"/></alternatives></inline-formula>&#x000a0;years (see Fig. <xref rid="Fig3" ref-type="fig">3</xref>a&#x02032;, b&#x02032;). In contrast, assuming that CA-125 can be produced also by healthy cells lead to an increase in tumour biomarker detection time to <inline-formula id="IEq237"><alternatives><tex-math id="M483">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}=10.07$$\end{document}</tex-math><mml:math id="M484"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>10.07</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq237.gif"/></alternatives></inline-formula> years; see Fig. <xref rid="Fig3" ref-type="fig">3</xref>a&#x02033;. However, assuming that IL-7 can be produced also by healthy cells lead to a decrease in immune biomarker detection time to <inline-formula id="IEq238"><alternatives><tex-math id="M485">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}=9.15$$\end{document}</tex-math><mml:math id="M486"><mml:mrow><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>9.15</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq238.gif"/></alternatives></inline-formula>; see Fig. <xref rid="Fig3" ref-type="fig">3</xref>b&#x02033;. This unexpected result is likely linked to the low cut-off value of IL-7 (as determined in [<xref ref-type="bibr" rid="CR14">14</xref>]). Choosing higher cut-off IL-7 values (as in [<xref ref-type="bibr" rid="CR18">18</xref>]) could delay the tumour detection time based on the immune biomarker; see Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Hence, the results of this study depend strongly on data we used from the published literature.</p><p id="Par48">Various clinical studies that investigated the relation between tumour size in early versus advanced cancers, have emphasised that early stage cancers grow locally to relatively large sizes (i.e., <inline-formula id="IEq239"><alternatives><tex-math id="M487">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003c;\,6$$\end{document}</tex-math><mml:math id="M488"><mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mspace width="0.166667em"/><mml:mn>6</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq239.gif"/></alternatives></inline-formula>&#x000a0;cm) before they are detected and/or spread [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Moreover, in the context of preclinical ovarian tumour sizes, [<xref ref-type="bibr" rid="CR44">44</xref>] suggested that achieving a 50% sensitivity in tumour detection before tumours reached advanced stages would require the detection of tumours of 1.3&#x000a0;cm diameter, while a 80% detection sensitivity would require the detection of tumour of 0.5&#x000a0;cm diameter. Assuming as in [<xref ref-type="bibr" rid="CR40">40</xref>], that tumours with diameters of 1&#x000a0;cm are formed of approximately <inline-formula id="IEq240"><alternatives><tex-math id="M489">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$10^{9}$$\end{document}</tex-math><mml:math id="M490"><mml:msup><mml:mn>10</mml:mn><mml:mn>9</mml:mn></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq240.gif"/></alternatives></inline-formula> cells (see Fig. 1B in [<xref ref-type="bibr" rid="CR40">40</xref>]), then a tumour of 0.5&#x000a0;cm diameter would contain approximately <inline-formula id="IEq241"><alternatives><tex-math id="M491">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$1.25\times 10^{8}$$\end{document}</tex-math><mml:math id="M492"><mml:mrow><mml:mn>1.25</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>8</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq241.gif"/></alternatives></inline-formula> cells (see also the calculation of tumour diameters at the end of &#x0201c;<xref rid="Sec2" ref-type="sec">Methods</xref>&#x0201d; section). Note that the tumour sizes calculated in Fig. <xref rid="Fig3" ref-type="fig">3</xref>c&#x02032;, c&#x02033;, in the context of immune biomarker detection, contain between <inline-formula id="IEq242"><alternatives><tex-math id="M493">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$1\times 10^{8} - 5\times 10^{8}$$\end{document}</tex-math><mml:math id="M494"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>8</mml:mn></mml:msup><mml:mo>-</mml:mo><mml:mn>5</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>8</mml:mn></mml:msup></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq242.gif"/></alternatives></inline-formula> cells (corresponding to tumours with diameters between 0.464&#x02013;0.79&#x000a0;cm). Hence, we suggest that the inclusion of immune biomarkers could increase also the detection sensitivity of ovarian cancers. Nevertheless, for a more detailed investigation of tumour detection sensitivity, we would need to fit model (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>) to patient data (an exercise that would also give us better information on the variability of different immune-related parameters).</p><p id="Par49">With the help of this mathematical model we also investigated the dependance of tumour detection times on the parameters controlling the immune response. In Fig. <xref rid="Fig5" ref-type="fig">5</xref> we showed that changes in the majority of immune-related parameters (e.g., <inline-formula id="IEq243"><alternatives><tex-math id="M495">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M496"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq243.gif"/></alternatives></inline-formula>, <inline-formula id="IEq244"><alternatives><tex-math id="M497">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$a_{i}$$\end{document}</tex-math><mml:math id="M498"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq244.gif"/></alternatives></inline-formula>, <italic>M</italic>, <inline-formula id="IEq245"><alternatives><tex-math id="M499">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{ei}$$\end{document}</tex-math><mml:math id="M500"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">ei</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq245.gif"/></alternatives></inline-formula>, <inline-formula id="IEq246"><alternatives><tex-math id="M501">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$f_{i}R_{i}$$\end{document}</tex-math><mml:math id="M502"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq246.gif"/></alternatives></inline-formula>)&#x02014;which could be the result of the heterogeneity in immune responses [<xref ref-type="bibr" rid="CR41">41</xref>]&#x02014;have significant impacts on the time when ovarian tumours are detected, and on the size of the tumour at detection time as shown in Fig. <xref rid="Fig8" ref-type="fig">8</xref>b&#x02013;g. Also changes in tumour-related parameters impact the time when the tumour is detected; see Fig. <xref rid="Fig7" ref-type="fig">7</xref>.</p><p id="Par50">In regard to tumour size at detection, we have seen that two parameters, <inline-formula id="IEq247"><alternatives><tex-math id="M503">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$d_{t}$$\end{document}</tex-math><mml:math id="M504"><mml:msub><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq247.gif"/></alternatives></inline-formula> and <inline-formula id="IEq248"><alternatives><tex-math id="M505">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M506"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq248.gif"/></alternatives></inline-formula>, do not seem to have any effect on tumour size when the tumour is detected. However, these two parameters do impact both biomarker detection times <inline-formula id="IEq249"><alternatives><tex-math id="M507">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M508"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq249.gif"/></alternatives></inline-formula> and <inline-formula id="IEq250"><alternatives><tex-math id="M509">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M510"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq250.gif"/></alternatives></inline-formula> (see Figs. <xref rid="Fig5" ref-type="fig">5</xref>a, <xref rid="Fig7" ref-type="fig">7</xref>a). This suggests that the change in these parameters (e.g., an increase in <inline-formula id="IEq251"><alternatives><tex-math id="M511">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k_{gr}$$\end{document}</tex-math><mml:math id="M512"><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="italic">gr</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq251.gif"/></alternatives></inline-formula> in Fig. <xref rid="Fig7" ref-type="fig">7</xref>a) leads to a change in detection times (e.g., a decrease in both <inline-formula id="IEq252"><alternatives><tex-math id="M513">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M514"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq252.gif"/></alternatives></inline-formula> and <inline-formula id="IEq253"><alternatives><tex-math id="M515">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M516"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq253.gif"/></alternatives></inline-formula>) which is opposite but of the same magnitude as the change in tumour size (e.g., increase in tumour size), so that there is no overall variation in tumour size at the new detection times. The interesting aspect is that this particular behaviour can be found only in the two parameters that affect both <inline-formula id="IEq254"><alternatives><tex-math id="M517">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M518"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq254.gif"/></alternatives></inline-formula> and <inline-formula id="IEq255"><alternatives><tex-math id="M519">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M520"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq255.gif"/></alternatives></inline-formula> at the same time (all other immune-related parameters affect only <inline-formula id="IEq256"><alternatives><tex-math id="M521">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{i}$$\end{document}</tex-math><mml:math id="M522"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq256.gif"/></alternatives></inline-formula>, and all tumour-related parameters affect only <inline-formula id="IEq257"><alternatives><tex-math id="M523">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$D_{T}^{t}$$\end{document}</tex-math><mml:math id="M524"><mml:msubsup><mml:mi>D</mml:mi><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msubsup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq257.gif"/></alternatives></inline-formula>). We believe that this is the effect of linear tumour growth and decay [although the decay term in Eq. (<xref rid="Equ1" ref-type="">1a</xref>) has the tumour variable <inline-formula id="IEq258"><alternatives><tex-math id="M525">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{T}$$\end{document}</tex-math><mml:math id="M526"><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq258.gif"/></alternatives></inline-formula> multiplied by a saturated term which depends on the immune response <inline-formula id="IEq259"><alternatives><tex-math id="M527">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{I}$$\end{document}</tex-math><mml:math id="M528"><mml:msub><mml:mi>N</mml:mi><mml:mi>I</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq259.gif"/></alternatives></inline-formula>; but for large <inline-formula id="IEq260"><alternatives><tex-math id="M529">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$N_{\text {I}}$$\end{document}</tex-math><mml:math id="M530"><mml:msub><mml:mi>N</mml:mi><mml:mtext>I</mml:mtext></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq260.gif"/></alternatives></inline-formula> this saturated term behaves as a constant].</p><p id="Par51">Finally, we showed in Fig. <xref rid="Fig9" ref-type="fig">9</xref>b that by creating a (<inline-formula id="IEq261"><alternatives><tex-math id="M531">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}},B_{\text {T}}$$\end{document}</tex-math><mml:math id="M532"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq261.gif"/></alternatives></inline-formula>) phase space diagram (corresponding to model dynamics for patient-specific immune and cancer parameters), we could predict the evolution of the tumour detection based on the solution trajectory crossing the cut-off limits <inline-formula id="IEq262"><alternatives><tex-math id="M533">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{CA125}$$\end{document}</tex-math><mml:math id="M534"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>C</mml:mi><mml:mi>A</mml:mi><mml:mn>125</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq262.gif"/></alternatives></inline-formula> and <inline-formula id="IEq263"><alternatives><tex-math id="M535">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$c_{IL7}$$\end{document}</tex-math><mml:math id="M536"><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>I</mml:mi><mml:mi>L</mml:mi><mml:mn>7</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq263.gif"/></alternatives></inline-formula>. We note here that the levels of CA-125 and IL-7 biomarkers could be in a space region that would not allow to distinguish between a healthy from a cancerous state (as observed clinically by [<xref ref-type="bibr" rid="CR14">14</xref>] for IL-7 <inline-formula id="IEq264"><alternatives><tex-math id="M537">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003e;3.8$$\end{document}</tex-math><mml:math id="M538"><mml:mrow><mml:mo>&#x0003e;</mml:mo><mml:mn>3.8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq264.gif"/></alternatives></inline-formula> and CA-125 <inline-formula id="IEq265"><alternatives><tex-math id="M539">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$&#x0003c;40$$\end{document}</tex-math><mml:math id="M540"><mml:mrow><mml:mo>&#x0003c;</mml:mo><mml:mn>40</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq265.gif"/></alternatives></inline-formula>, in the case of benign vs. malignant tumour; see also Fig. <xref rid="Fig9" ref-type="fig">9</xref>a). However, the construction of a (<inline-formula id="IEq266"><alternatives><tex-math id="M541">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$B_{\text {I}},B_{\text {T}}$$\end{document}</tex-math><mml:math id="M542"><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mtext>I</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mtext>T</mml:mtext></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq266.gif"/></alternatives></inline-formula>) diagram&#x02014;for patient-specific parameters&#x02014;could allow us to make predictions regarding the long-term evolution of the biomarker levels in individual patients.</p><p id="Par52">Given the simplicity of the mathematical model (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>), this study could not be applied to make predictions regarding benign versus malignant tumours (and thus we discuss our results in terms of &#x0201c;healthy&#x0201d; versus &#x0201c;cancerous&#x0201d; states). Future work on this topic would see a generalisation of model (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>) to include also a benign tumour&#x02014;to test the predictions of this particular model for the detection of either malignant or benign tumours (based on the CA-125/IL-7 classification of [<xref ref-type="bibr" rid="CR14">14</xref>]). Another restriction of this study is related to the multifaceted role of IL-7: on boosting the immune response [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], and on the possibility of IL-7 to act as a growth factor for ovarian cancer cells [<xref ref-type="bibr" rid="CR14">14</xref>]. In addition, the CA-125 marker seems to have a (less understood) role in the immune response, for example by inhibiting the cytotoxic responses of NK cells [<xref ref-type="bibr" rid="CR47">47</xref>], which requires further investigation.</p><p id="Par53">Finally, given the complexity of the ovarian cancer evolution (which is evident from the heterogeneity of these cancers [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]), one could say that such simple mathematical models could be useless for understanding the disease. However, the goal of these simple models is not to reproduce all the details of the disease. Rather, these models could be used to identify common biological characteristics that can be further investigated experimentally [<xref ref-type="bibr" rid="CR24">24</xref>]. The model introduced in this study (which focused on two very general cancer and immune biomarkers) can be easily generalised (see the discussion in [<xref ref-type="bibr" rid="CR24">24</xref>]) to incorporate more complex aspects of ovarian cancer evolution: different cancer clone populations with different growth rates and different surface markers [<xref ref-type="bibr" rid="CR51">51</xref>], or changes in the core molecules of different canonical pathways (such as PTEN, notch, PI3K/AKT, etc.) [<xref ref-type="bibr" rid="CR51">51</xref>], or multiple cancer/immune biomarkers that might be associated also with different subtypes of ovarian carcinoma [<xref ref-type="bibr" rid="CR52">52</xref>]. Moreover, the interaction rates between the different components of the system, as well as the cells proliferation/death rates and the biomarker secretion rates, could be made probabilistic. Such generalisations can transform the simple differential equations model (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>) into more complex deterministic and stochastic network models [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], which can include more biological realism. In the future, we will consider also a generalisation of model (<xref rid="Equ1" ref-type="">1</xref>)&#x02013;(<xref rid="Equ4" ref-type="">3</xref>) to investigate multiple biomarker detection in the context of heterogeneous ovarian cancers. The relevant cancer biomarkers to be used in this model could be identified with the help of network models (see, for example, [<xref ref-type="bibr" rid="CR31">31</xref>]).</p></sec><sec id="Sec10"><title>Conclusions</title><p id="Par54">Using a new mathematical model, we investigated the dynamics of cancer-immune interactions and biomarker secretion by both immune and cancer cells, and showed that variations in immune-related parameters can affect the tumour detection times. Since in addition to tumour immune modulation there are many other factors that affect the level of immune responses&#x02014;e.g., unrelated infections which lead to an active immune response and increased secretion of IL-7 (as in HIV infections [<xref ref-type="bibr" rid="CR55">55</xref>] or <italic>A. benhamiae</italic> infections [<xref ref-type="bibr" rid="CR56">56</xref>]), making accurate predictions regarding tumour detection times (based on both tumour and immune biomarkers) might depend significantly on the status of immune response in each patient. This idea is consistent with many other recent studies that discussed the promises and pitfalls of immune biomarkers as personalised medicines [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. However, the mathematical framework presented here could take the research one step further by incorporating patient-specific parameters (e.g., different levels of immune activation or biomarker secretion), and through the use of mathematical tools (e.g., sensitivity analysis or bifurcation diagrams) one could get a better understanding of the time-evolution of the tumour&#x02013;immune-biomarker system.</p><p id="Par55">To be able to use this model for predictive clinical purposes, one needs to have accurate data (at multiple time points) on the level of immune responses, as well as the levels of tumour and immune biomarkers and their cut-off values. We showed in Fig. <xref rid="Fig4" ref-type="fig">4</xref> that changes in the cut-off values of IL-7 (corresponding to the values published in different clinical studies; see [<xref ref-type="bibr" rid="CR14">14</xref>] vs. [<xref ref-type="bibr" rid="CR18">18</xref>]) leads to different predictions regarding the detection of cancer based on immune biomarkers. However, once this data is available, such a mathematical model could be applied to individual patients.</p><p id="Par56">We conclude by mentioning that since high levels of CA-125 are not exclusive to ovarian cancers (being found also in patients with breast, lung or gastrointestinal cancers [<xref ref-type="bibr" rid="CR2">2</xref>]), and since IL-7 is a cytokine that characterises an active immune response, we hypothesise that a combined use of CA-125 and IL-7 could be employed to detect possible early signs of other types of cancers. In this case, other tumour/immune biomarkers need to be used in combination with CA-125/IL-7, to increase the specificity towards ovarian cancers [<xref ref-type="bibr" rid="CR9">9</xref>], or towards other cancers.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ODE</term><def><p id="Par2">ordinary differential equation</p></def></def-item><def-item><term>CA-125</term><def><p id="Par3">carbohydrate antigen 125</p></def></def-item><def-item><term>IL-7</term><def><p id="Par4">interleukin 7</p></def></def-item><def-item><term>HE4</term><def><p id="Par5">human epididymal secretory protein 4</p></def></def-item><def-item><term>G-CSF</term><def><p id="Par6">granulocyte-colony stimulating factor</p></def></def-item><def-item><term>uPAR</term><def><p id="Par7">urokinase-type plasminogen activator receptor</p></def></def-item><def-item><term>SEAP</term><def><p id="Par8">secreted embryonic alkaline phosphatase</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>RE designed the study. RE and EH performed the simulations and wrote the paper. Both authors read and approved the final manuscript.</p><sec id="d29e6805"><title>Acknowledgements</title><p>Not applicable.</p></sec><sec id="d29e6810"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="d29e6815"><title>Availability of data and materials</title><p>Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p></sec><sec id="d29e6820"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="d29e6825"><title>Ethics approval and consent to participate</title><p>Not applicable.</p></sec><sec id="d29e6830"><title>Funding</title><p>Not applicable.</p></sec><sec id="d29e6835"><title>Publisher's Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oza</surname><given-names>AM</given-names></name><name><surname>Cook</surname><given-names>AD</given-names></name><name><surname>Pfisterer</surname><given-names>J</given-names></name><name><surname>Embleton</surname><given-names>A</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Pujade-Lauraine</surname><given-names>E</given-names></name><name><surname>Kristensen</surname><given-names>G</given-names></name><name><surname>Carey</surname><given-names>MS</given-names></name><name><surname>Beale</surname><given-names>P</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Park-Simon</surname><given-names>T-W</given-names></name><name><surname>Rustin</surname><given-names>G</given-names></name><name><surname>Joly</surname><given-names>F</given-names></name><name><surname>Mirza</surname><given-names>MR</given-names></name><name><surname>Plante</surname><given-names>M</given-names></name><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Poveda</surname><given-names>A</given-names></name><name><surname>Jayson</surname><given-names>GC</given-names></name><name><surname>Stark</surname><given-names>D</given-names></name><name><surname>Swart</surname><given-names>AM</given-names></name><name><surname>Farrelly</surname><given-names>L</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Parmar</surname><given-names>MKB</given-names></name><name><surname>Perren</surname><given-names>TJ</given-names></name></person-group><article-title>Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>8</issue><fpage>928</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00086-8</pub-id><pub-id pub-id-type="pmid">26115797</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepin</surname><given-names>K</given-names></name><name><surname>del Carmen</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Dizon</surname><given-names>DS</given-names></name></person-group><article-title>Ca125 and epithelial ovarian cancer: role in screening, diagnosis and surveillance</article-title><source>Am J Hematol Oncol</source><year>2014</year><volume>10</volume><issue>6</issue><fpage>22</fpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>I</given-names></name><name><surname>Oswald</surname><given-names>M</given-names></name><name><surname>Lovecchio</surname><given-names>J</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Menzin</surname><given-names>A</given-names></name><name><surname>Whyte</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>LD</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Bhuiya</surname><given-names>T</given-names></name><name><surname>Keogh</surname><given-names>M</given-names></name><name><surname>Mason</surname><given-names>C</given-names></name><name><surname>Sultan</surname><given-names>K</given-names></name><name><surname>Budman</surname><given-names>D</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name></person-group><article-title>Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes</article-title><source>Br J Cancer</source><year>2014</year><volume>110</volume><issue>4</issue><fpage>976</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.795</pub-id><pub-id pub-id-type="pmid">24366298</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor</surname><given-names>G</given-names></name><name><surname>Visintin</surname><given-names>I</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>P</given-names></name><name><surname>Rutherford</surname><given-names>T</given-names></name><name><surname>Yue</surname><given-names>L</given-names></name><name><surname>Bray-Ward</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>DC</given-names></name></person-group><article-title>Serum protein markers for early cancer detection of ovarian cancer</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><issue>21</issue><fpage>7677</fpage><lpage>7682</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502178102</pub-id><pub-id pub-id-type="pmid">15890779</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JG</given-names></name><name><surname>White</surname><given-names>M</given-names></name><name><surname>Cruz</surname><given-names>A</given-names></name><name><surname>Farias-Eisner</surname><given-names>R</given-names></name></person-group><article-title>In 2014, can we do better than CA125 in the early detection of ovarian cancer</article-title><source>World J Biol Chem</source><year>2014</year><volume>5</volume><issue>3</issue><fpage>286</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.4331/wjbc.v5.i3.286</pub-id><pub-id pub-id-type="pmid">25225597</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>McIntosh</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Barnett</surname><given-names>M</given-names></name><name><surname>Goodman</surname><given-names>G</given-names></name><name><surname>Thorpe</surname><given-names>JD</given-names></name><name><surname>Bergan</surname><given-names>L</given-names></name><name><surname>Thornquist</surname><given-names>MD</given-names></name><name><surname>Scholler</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>O&#x02019;Briant</surname><given-names>K</given-names></name><name><surname>Drescher</surname><given-names>C</given-names></name><name><surname>Urban</surname><given-names>N</given-names></name></person-group><article-title>Assessing lead time of selected ovarian cancer biomarkers: a nested case&#x02013;control study</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp438</pub-id><pub-id pub-id-type="pmid">20042715</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholler</surname><given-names>N</given-names></name><name><surname>Urban</surname><given-names>N</given-names></name></person-group><article-title>Ca125 in ovarian cancer</article-title><source>Biomark Med</source><year>2007</year><volume>1</volume><issue>4</issue><fpage>513</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.2217/17520363.1.4.513</pub-id><pub-id pub-id-type="pmid">20477371</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>EL</given-names></name><name><surname>Hollingworth</surname><given-names>J</given-names></name><name><surname>Reynolds</surname><given-names>TM</given-names></name></person-group><article-title>The role of CA125 in clinical practice</article-title><source>J Clin Pathol</source><year>2005</year><volume>58</volume><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1136/jcp.2004.018077</pub-id><pub-id pub-id-type="pmid">15735166</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Atkinson</surname><given-names>JN</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Diamandis</surname><given-names>EP</given-names></name><name><surname>Hellstrom</surname><given-names>I</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><name><surname>Liu</surname><given-names>J</given-names><suffix>Jr</suffix></name></person-group><article-title>R.C.B.: potential markers that complement expression of ca125 in epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><year>2005</year><volume>99</volume><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2005.06.040</pub-id><pub-id pub-id-type="pmid">16061277</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolen</surname><given-names>BM</given-names></name><name><surname>Lokshin</surname><given-names>AE</given-names></name></person-group><article-title>Multianalyte assay systems in the differential diagnosis of ovarian cancer</article-title><source>Expert Opin Med Diagn</source><year>2012</year><volume>6</volume><issue>2</issue><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1517/17530059.2012.661711</pub-id><pub-id pub-id-type="pmid">22468148</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>RI</given-names></name><name><surname>Lubsen-Brandsma</surname><given-names>MA</given-names></name><name><surname>Verhoef</surname><given-names>S</given-names></name><name><surname>van Beurden</surname><given-names>M</given-names></name></person-group><article-title>CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer</article-title><source>Gynecol Oncol</source><year>2006</year><volume>100</volume><issue>1</issue><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2005.08.038</pub-id><pub-id pub-id-type="pmid">16188302</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholler</surname><given-names>N</given-names></name><name><surname>Crawford</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Drescher</surname><given-names>CW</given-names></name><name><surname>O&#x02019;Briant</surname><given-names>KC</given-names></name><name><surname>Kiviat</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Urban</surname><given-names>N</given-names></name></person-group><article-title>Bead-based ELISA for validation of ovarian cancer early detection markers</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>2117</fpage><lpage>2124</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2007</pub-id><pub-id pub-id-type="pmid">16609024</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>M</given-names></name><name><surname>Bahaa</surname><given-names>A</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Hakem</surname><given-names>AAE</given-names></name><name><surname>Noor</surname><given-names>AA-E</given-names></name><name><surname>Tohamy</surname><given-names>UE</given-names></name></person-group><article-title>Evaluation of serum mesothelin in malignant and ovarian benign ovarian masses</article-title><source>Arch Gynecol Obstet</source><year>2014</year><volume>290</volume><issue>1</issue><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">24445964</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambeck</surname><given-names>AJA</given-names></name><name><surname>Crijns</surname><given-names>APG</given-names></name><name><surname>Leffers</surname><given-names>N</given-names></name><name><surname>Sluiter</surname><given-names>WJ</given-names></name><name><surname>ten Hoor</surname><given-names>KA</given-names></name><name><surname>Braid</surname><given-names>M</given-names></name><name><surname>van der Zee</surname><given-names>AGJ</given-names></name><name><surname>Daemen</surname><given-names>T</given-names></name><name><surname>Nijman</surname><given-names>HW</given-names></name><name><surname>Kast</surname><given-names>WM</given-names></name></person-group><article-title>Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>8</issue><fpage>2385</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1828</pub-id><pub-id pub-id-type="pmid">17438097</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jammal</surname><given-names>MP</given-names></name><name><surname>Martins-Filho</surname><given-names>A</given-names></name><name><surname>Silveira</surname><given-names>TP</given-names></name><name><surname>Murta</surname><given-names>EFC</given-names></name><name><surname>Nomelini</surname><given-names>RS</given-names></name></person-group><article-title>Cytokines and prognostic factors in epithelial ovarian cancer</article-title><source>Clin Med Insights Oncol</source><year>2016</year><volume>10</volume><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.4137/CMO.S38333</pub-id><pub-id pub-id-type="pmid">27512342</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>YY</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name></person-group><article-title>Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><fpage>10267</fpage><lpage>10280</lpage><pub-id pub-id-type="doi">10.3390/ijms160510267</pub-id><pub-id pub-id-type="pmid">25955647</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Wakefield</surname><given-names>MR</given-names></name><name><surname>Ding</surname><given-names>VA</given-names></name><name><surname>Bai</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name></person-group><article-title>The role of IL-7 in immunity and cancer</article-title><source>Anticancer Res</source><year>2017</year><volume>37</volume><issue>3</issue><fpage>963</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11405</pub-id><pub-id pub-id-type="pmid">28314253</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name></person-group><article-title>Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma</article-title><source>Int J Gynecol Obstet</source><year>2004</year><volume>85</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.ijgo.2003.08.015</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuntoli</surname><given-names>RL</given-names></name><name><surname>Webb</surname><given-names>TJ</given-names></name><name><surname>Zoso</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>O</given-names></name><name><surname>Diaz-Montes</surname><given-names>TP</given-names></name><name><surname>Bristow</surname><given-names>RE</given-names></name><name><surname>Oelke</surname><given-names>M</given-names></name></person-group><article-title>Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumour immunity</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><fpage>2875</fpage><lpage>2884</lpage><pub-id pub-id-type="pmid">19661290</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>V</given-names></name><name><surname>Dinh</surname><given-names>TV</given-names></name><name><surname>Hannigan</surname><given-names>EV</given-names></name></person-group><article-title>Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis</article-title><source>Cancer J Sci Am</source><year>1996</year><volume>2</volume><issue>5</issue><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">9166545</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoiemma</surname><given-names>PP</given-names></name><name><surname>Powell</surname><given-names>DJ</given-names></name></person-group><article-title>Tumour infiltrating lymphocytes in ovarian cancer</article-title><source>Cancer Biol Ther</source><year>2015</year><volume>16</volume><issue>6</issue><fpage>807</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1080/15384047.2015.1040960</pub-id><pub-id pub-id-type="pmid">25894333</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milne</surname><given-names>K</given-names></name><name><surname>K&#x000f6;bel</surname><given-names>M</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><name><surname>Barnes</surname><given-names>RO</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Gilks</surname><given-names>CB</given-names></name><name><surname>Watson</surname><given-names>PH</given-names></name><name><surname>Nelson</surname><given-names>BH</given-names></name></person-group><article-title>Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><issue>7</issue><fpage>6412</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0006412</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>SF</given-names></name><name><surname>Benencia</surname><given-names>F</given-names></name></person-group><article-title>Immunotherapy for ovarian cancer: what are the targets of the future?</article-title><source>Future Oncol</source><year>2015</year><volume>11</volume><issue>9</issue><fpage>1293</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.2217/fon.15.44</pub-id><pub-id pub-id-type="pmid">25952776</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eftimie</surname><given-names>R</given-names></name><name><surname>Gillard</surname><given-names>JJ</given-names></name><name><surname>Cantrell</surname><given-names>DA</given-names></name></person-group><article-title>Mathematical models for immunology: current state of the art and future research directions</article-title><source>Bull Math Biol</source><year>2016</year><volume>78</volume><issue>10</issue><fpage>2091</fpage><lpage>2134</lpage><pub-id pub-id-type="doi">10.1007/s11538-016-0214-9</pub-id><pub-id pub-id-type="pmid">27714570</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>SS</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name></person-group><article-title>Mathematical model identified blood biomarker-based early cancer detection strategies and limitations</article-title><source>Sci Transl Med</source><year>2011</year><volume>3</volume><issue>109</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3003110</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>AM</given-names></name><name><surname>Willmann</surname><given-names>JK</given-names></name><name><surname>Cochran</surname><given-names>FV</given-names></name><name><surname>Ray</surname><given-names>P</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name></person-group><article-title>Cancer screening: a mathematical model relating secreted blood biomarker levels to tumour sizes</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>170</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0050170</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>SS</given-names></name><name><surname>Lutz</surname><given-names>AM</given-names></name><name><surname>Paulmurugan</surname><given-names>R</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name></person-group><article-title>A model-based personalised cancer screening strategy for detecting early-stage tumours using blood-borne biomarkers</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><issue>10</issue><fpage>2570</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2904</pub-id><pub-id pub-id-type="pmid">28283654</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>W</given-names></name><name><surname>Friedman</surname><given-names>A</given-names></name></person-group><article-title>Serum uPAR as biomarker in breast cancer recurrence: a mathematical model</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><issue>4</issue><fpage>0153508</fpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>GA</given-names></name><name><surname>Dudani</surname><given-names>JS</given-names></name><name><surname>Carrodeguas</surname><given-names>E</given-names></name><name><surname>Mazumdar</surname><given-names>EV</given-names></name><name><surname>Zekavat</surname><given-names>SM</given-names></name><name><surname>Bhatia</surname><given-names>SN</given-names></name></person-group><article-title>Mathematical framework for activity-based cancer biomarkers</article-title><source>Proc Natl Acad Sci USA</source><year>2015</year><volume>112</volume><issue>41</issue><fpage>12627</fpage><lpage>12632</lpage><pub-id pub-id-type="doi">10.1073/pnas.1506925112</pub-id><pub-id pub-id-type="pmid">26417077</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilar</surname><given-names>S</given-names></name><name><surname>Gonz&#x000e4;les-D&#x000ed;az</surname><given-names>H</given-names></name><name><surname>Santana</surname><given-names>L</given-names></name><name><surname>Uriarte</surname><given-names>E</given-names></name></person-group><article-title>QSAR model for alignment-free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP-lattice networks</article-title><source>J Comput Chem</source><year>2008</year><volume>29</volume><issue>16</issue><fpage>2613</fpage><lpage>2622</lpage><pub-id pub-id-type="doi">10.1002/jcc.21016</pub-id><pub-id pub-id-type="pmid">18478581</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilar</surname><given-names>S</given-names></name><name><surname>Gonz&#x000e4;les-D&#x000ed;az</surname><given-names>H</given-names></name><name><surname>Santana</surname><given-names>L</given-names></name><name><surname>Uriarte</surname><given-names>E</given-names></name></person-group><article-title>A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer</article-title><source>J Theor Biol</source><year>2009</year><volume>261</volume><issue>3</issue><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2009.07.031</pub-id><pub-id pub-id-type="pmid">19654012</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>B-S</given-names></name></person-group><article-title>A network-based biomarker approach for molecular investigation and diagnosis of lung cancer</article-title><source>BMC Med Genom</source><year>2011</year><volume>4</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1755-8794-4-2</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>S-Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Network biomarkers reveal dysfunctional gene regulations during disease progression</article-title><source>FEBS J</source><year>2013</year><volume>280</volume><fpage>5682</fpage><lpage>5695</lpage><pub-id pub-id-type="doi">10.1111/febs.12536</pub-id><pub-id pub-id-type="pmid">24107168</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tisoncik</surname><given-names>JR</given-names></name><name><surname>Korth</surname><given-names>MJ</given-names></name><name><surname>Simmons</surname><given-names>CP</given-names></name><name><surname>Farrar</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>TR</given-names></name><name><surname>Katze</surname><given-names>MG</given-names></name></person-group><article-title>Into the eye of the cytokine storm</article-title><source>Microbiol Mol Biol Rev</source><year>2012</year><volume>76</volume><issue>1</issue><fpage>16</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1128/MMBR.05015-11</pub-id><pub-id pub-id-type="pmid">22390970</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Nash</surname><given-names>J</given-names></name><name><surname>Runowicz</surname><given-names>C</given-names></name><name><surname>Swede</surname><given-names>H</given-names></name><name><surname>Stevens</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Ovarian cancer immunotherapy: opportunities, progresses and challenges</article-title><source>J Hemat Oncol</source><year>2010</year><volume>3</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1756-8722-3-7</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Boer</surname><given-names>RJ</given-names></name><name><surname>Homann</surname><given-names>D</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><article-title>Different dynamics of CD4<inline-formula id="IEq269"><alternatives><tex-math id="M543">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M544"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq269.gif"/></alternatives></inline-formula> and CD8<inline-formula id="IEq270"><alternatives><tex-math id="M545">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$^{+}$$\end{document}</tex-math><mml:math id="M546"><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:math><inline-graphic xlink:href="12967_2018_1432_Article_IEq270.gif"/></alternatives></inline-formula> T cell response during and after acute lymphocytic choriomeningitis virus infection</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>3928</fpage><lpage>3935</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.8.3928</pub-id><pub-id pub-id-type="pmid">14530309</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Shabier</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Regulation of the lifespan in dendritic cell subsets</article-title><source>Mol Immunol</source><year>2007</year><volume>44</volume><issue>10</issue><fpage>2558</fpage><lpage>2565</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2006.12.020</pub-id><pub-id pub-id-type="pmid">17267035</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sport&#x000e8;s</surname><given-names>C</given-names></name><name><surname>Babb</surname><given-names>RR</given-names></name><name><surname>Krumlauf</surname><given-names>MC</given-names></name><name><surname>Hakim</surname><given-names>FT</given-names></name><name><surname>Steinberg</surname><given-names>SM</given-names></name><name><surname>Chow</surname><given-names>CK</given-names></name><name><surname>Brown</surname><given-names>MR</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Noel</surname><given-names>P</given-names></name><name><surname>Maric</surname><given-names>I</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>M</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Buffet</surname><given-names>R</given-names></name><name><surname>Morre</surname><given-names>M</given-names></name><name><surname>Amato</surname><given-names>RJ</given-names></name><name><surname>Pecora</surname><given-names>A</given-names></name><name><surname>Mackall</surname><given-names>CL</given-names></name><name><surname>Gress</surname><given-names>RE</given-names></name></person-group><article-title>Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><issue>2</issue><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1303</pub-id><pub-id pub-id-type="pmid">20068111</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mengus</surname><given-names>C</given-names></name><name><surname>Le Magnen</surname><given-names>C</given-names></name><name><surname>Trella</surname><given-names>E</given-names></name><name><surname>Yousef</surname><given-names>K</given-names></name><name><surname>Bubendorf</surname><given-names>L</given-names></name><name><surname>Provenzano</surname><given-names>M</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name><name><surname>Heberer</surname><given-names>M</given-names></name><name><surname>Spagnoli</surname><given-names>GC</given-names></name><name><surname>Wyler</surname><given-names>S</given-names></name></person-group><article-title>Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer</article-title><source>J Transl Med</source><year>2011</year><volume>9</volume><fpage>162</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-9-162</pub-id><pub-id pub-id-type="pmid">21943235</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friberg</surname><given-names>S</given-names></name><name><surname>Mattson</surname><given-names>S</given-names></name></person-group><article-title>On the growth rates of human malignant tumours: implications for medical decision making</article-title><source>J Surg Oncol</source><year>1997</year><volume>65</volume><fpage>284</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9098(199708)65:4&#x0003c;284::AID-JSO11&#x0003e;3.0.CO;2-2</pub-id><pub-id pub-id-type="pmid">9274795</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name></person-group><article-title>Heterogeneity in immune responses: from populations to single cells</article-title><source>Trends Immunol</source><year>2014</year><volume>35</volume><issue>5</issue><fpage>219</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.it.2014.03.004</pub-id><pub-id pub-id-type="pmid">24746883</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Mendelsohn</surname><given-names>A</given-names></name><name><surname>Larrick</surname><given-names>JW</given-names></name></person-group><article-title>Interleukin-7 and immunosenecence</article-title><source>J Immunol Res</source><year>2017</year><volume>2017</volume><fpage>4807853</fpage><pub-id pub-id-type="doi">10.1155/2017/4807853</pub-id><pub-id pub-id-type="pmid">28484723</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mongia</surname><given-names>S</given-names></name><name><surname>Rawlins</surname><given-names>M</given-names></name><name><surname>Owen</surname><given-names>W</given-names></name><name><surname>Roberts</surname><given-names>W</given-names></name></person-group><article-title>Performance characteristics of seven automated CA125 assays</article-title><source>Am J Clin Pathol</source><year>2005</year><volume>125</volume><issue>6</issue><fpage>921</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1309/NBA312W0LANRXYH9</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>PO</given-names></name><name><surname>Palmer</surname><given-names>C</given-names></name></person-group><article-title>The preclinical natural history of serous ovarian cancer: defining the target for early detection</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><fpage>1000114</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000114</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stratton</surname><given-names>JF</given-names></name><name><surname>Pharoah</surname><given-names>P</given-names></name><name><surname>Tidy</surname><given-names>JA</given-names></name><name><surname>Paterson</surname><given-names>ME</given-names></name></person-group><article-title>An analysis of ovarian tumour diameter and survival</article-title><source>Int J Gynecol Cancer</source><year>2000</year><volume>10</volume><issue>6</issue><fpage>449</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1438.2000.00070.x</pub-id><pub-id pub-id-type="pmid">11240713</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horwath</surname><given-names>LE</given-names></name><name><surname>Werner</surname><given-names>T</given-names></name><name><surname>Boucher</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name></person-group><article-title>The relationship between tumour size and stage in early versus advanced ovarian cancer</article-title><source>Med Hypotheses</source><year>2013</year><volume>80</volume><fpage>684</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2013.01.027</pub-id><pub-id pub-id-type="pmid">23474070</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belisle</surname><given-names>JA</given-names></name><name><surname>Gubbels</surname><given-names>JAA</given-names></name><name><surname>Raphael</surname><given-names>CA</given-names></name><name><surname>Migneault</surname><given-names>M</given-names></name><name><surname>Rancourt</surname><given-names>C</given-names></name><name><surname>Connor</surname><given-names>JP</given-names></name><name><surname>Patankar</surname><given-names>MS</given-names></name></person-group><article-title>Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)</article-title><source>Immunology</source><year>2007</year><volume>122</volume><fpage>418</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02660.x</pub-id><pub-id pub-id-type="pmid">17617155</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Welch</surname><given-names>W</given-names></name><name><surname>Bell</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>Y-F</given-names></name><name><surname>Berkowitz</surname><given-names>R</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><name><surname>Bandera</surname><given-names>CA</given-names></name></person-group><article-title>Ovarian cancer is a heterogeneous disease</article-title><source>Cancer Genet Cytogenet</source><year>2005</year><volume>161</volume><issue>2</issue><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.12.014</pub-id><pub-id pub-id-type="pmid">16102589</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meinhold-Heerlein</surname><given-names>I</given-names></name><name><surname>Hauptmann</surname><given-names>S</given-names></name></person-group><article-title>The heterogeneity of ovarian cancer</article-title><source>Arch Gynecol Obstet</source><year>2014</year><volume>289</volume><issue>2</issue><fpage>237</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1007/s00404-013-3114-3</pub-id><pub-id pub-id-type="pmid">24318356</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroeger</surname><given-names>PT</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name></person-group><article-title>Pathogenesis and heterogeneity of ovarian cancer</article-title><source>Curr Opin Obstet Gynecol</source><year>2017</year><volume>29</volume><issue>1</issue><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1097/GCO.0000000000000340</pub-id><pub-id pub-id-type="pmid">27898521</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YP</given-names></name><name><surname>Shim</surname><given-names>HS</given-names></name><name><surname>Gao</surname><given-names>M-Q</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>NH</given-names></name></person-group><article-title>Molecular portraits of intratumoral heterogeneity in human ovarian cancer</article-title><source>Cancer Lett</source><year>2011</year><volume>307</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.03.018</pub-id><pub-id pub-id-type="pmid">21481528</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolen</surname><given-names>BM</given-names></name><name><surname>Lokshin</surname><given-names>AE</given-names></name></person-group><article-title>Protein biomarkers of ovarian cancer: the forest and the trees</article-title><source>Future Oncol</source><year>2012</year><volume>8</volume><issue>1</issue><fpage>55</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.2217/fon.11.135</pub-id><pub-id pub-id-type="pmid">22149035</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreeger</surname><given-names>PK</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name></person-group><article-title>Cancer systems biology: a network modeling perspective</article-title><source>Carcinogenesis</source><year>2010</year><volume>31</volume><issue>1</issue><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp261</pub-id><pub-id pub-id-type="pmid">19861649</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>RH</given-names></name><name><surname>Trichler</surname><given-names>DL</given-names></name><name><surname>Gaille</surname><given-names>DP</given-names></name></person-group><article-title>Mathematical and statistical modeling in cancer systems biology</article-title><source>Front Physiol</source><year>2012</year><volume>3</volume><fpage>227</fpage><pub-id pub-id-type="doi">10.3389/fphys.2012.00227</pub-id><pub-id pub-id-type="pmid">22754537</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napolitano</surname><given-names>LA</given-names></name><name><surname>Grant</surname><given-names>RM</given-names></name><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Rosa</surname><given-names>SCD</given-names></name><name><surname>Herzenberg</surname><given-names>LA</given-names></name><name><surname>Herndier</surname><given-names>BG</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>McCune</surname><given-names>JM</given-names></name></person-group><article-title>Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/83381</pub-id><pub-id pub-id-type="pmid">11135619</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraki</surname><given-names>Y</given-names></name><name><surname>Ishibashi</surname><given-names>Y</given-names></name><name><surname>Hiruma</surname><given-names>M</given-names></name><name><surname>Nishikawa</surname><given-names>A</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name></person-group><article-title>Cytokine secretion profiles of human keratinocytes during <italic>Trichophyton tonsurans</italic> and <italic>Arthroderma benhamiae</italic> infections</article-title><source>J Med Microbiol</source><year>2006</year><volume>55</volume><fpage>1175</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.46632-0</pub-id><pub-id pub-id-type="pmid">16914646</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name><name><surname>Brunet</surname><given-names>LR</given-names></name><name><surname>Butler</surname><given-names>MO</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Hakansson</surname><given-names>LG</given-names></name><name><surname>Hanks</surname><given-names>BA</given-names></name><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Khleif</surname><given-names>SN</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Miller</surname><given-names>LD</given-names></name><name><surname>Schendel</surname><given-names>DJ</given-names></name><name><surname>Tanneau</surname><given-names>I</given-names></name><name><surname>Wigginton</surname><given-names>JM</given-names></name><name><surname>Butterfield</surname><given-names>LH</given-names></name></person-group><article-title>Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy</article-title><source>J Immuno Ther Cancer</source><year>2017</year><volume>5</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/s40425-017-0243-4</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>JCD</given-names></name><name><surname>Lord</surname><given-names>GM</given-names></name></person-group><article-title>Immune biomarkers: the promises and pitfalls of personalised medicine</article-title><source>Nat Rev Immunol</source><year>2015</year><volume>15</volume><issue>5</issue><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/nri3820</pub-id><pub-id pub-id-type="pmid">25814400</pub-id></element-citation></ref></ref-list></back></article>